

Sonogashira diversification of unprotected halotryptophans, halotryptophan containing tripeptides; and generation of a new to nature bromo-natural product and its diversification in water

M. J. Corr,^a S. V. Sharma,^a C. Pubill-Ulldemolins,^a R. T. Bown,^a P. Poirot,^b D. R. Smith,^a C. Cartmell,^a A. Abou Fayad,^c R. J. M. Goss^{a*}

Supporting Information

<i>General Synthetic Experimental</i>	Page number
Experimental For the synthesis of: Sodium 2'-(Dicyclohexylphosphanyl)-2,6-diisopropyl-(1,1-biphenyl)-4-sulfonate (sXPhos) 12 ²	4
Standard Reaction Procedure of 5-bromoindole 15 under reflux:	5
Microwave Reaction Procedure of 5-bromoindole 15 :	5
Standard Microwave Reaction Procedure for Tryptophans:	5
(<i>S</i>)-2-Amino-3-(5-(phenylethynyl)-1 <i>H</i> -indol-3-yl)propanoic acid 19	6
(<i>S</i>)-2-Amino-3-5-((3-fluorophenyl)ethynyl)-1 <i>H</i> -indol-3-yl)propanoic acid 36	7
(<i>S</i>)-2-Amino-3-5-((4-cyanophenyl)ethynyl)-1 <i>H</i> -indol-3-yl)propanoic acid 39	7
(<i>S</i>)-2-Amino-3-(5-(thiophen-3-ylethynyl)-1 <i>H</i> -indol-3-yl)propanoic acid 42	8
(<i>S</i>)-2-Amino-3-(5-(4-hydroxybut-1-yn-1-yl)-1 <i>H</i> -indol-3-yl)propanoic acid 45	9
(<i>S</i>)-2-Amino-3-(5-(4-phenylbut-1-yn-1-yl)-1 <i>H</i> -indol-3-yl)propanoic acid 48	9
(<i>S</i>)-2-Amino-3-(5-(octa-1,7-diyn-1-yl)-1 <i>H</i> -indol-3-yl)propanoic acid 51	10
(<i>S</i>)-2-Amino-3-(3-cyclohexylprop-1-yn-1-yl)-1 <i>H</i> -indol-3-yl)propanoic acid 54	10
<i>N</i> -Boc-7-bromo- <i>S</i> -tryptophan 66	11
7-Bromo- <i>L</i> -tryptophan methyl ester hydrochloride 67	12
<i>N</i> -Boc-Ala-Phe-OMe 68	12
H-Ala-Phe-OMe.TFA 69	13
<i>N</i> -Boc-Trp-(7-Br)-Ala-Phe-OMe 70	14
H-Trp-(7-Br)-Ala-Phe-OH 59	15
<i>N</i> -Boc-Trp-(7-Br)-Phe-OMe 71	16
<i>N</i> -Boc-Ala-Trp-(7-Br)-Phe-OMe 72	17
H-Ala-Trp-(7-Br)-Phe-OH 58	18
((<i>S</i>)-2-((<i>S</i>)-2-Aminopropanamido)-3-(7-((3-fluorophenyl)ethynyl)-1 <i>H</i> -indol-3-yl)propanoyl)- <i>L</i> -phenylalanine 60	19
((<i>S</i>)-2-Amino-3-(7-((3-fluorophenyl)ethynyl)-1 <i>H</i> -indol-3-yl)propanoyl)- <i>L</i> -alanyl- <i>L</i> -phenylalanine 61	20
Enantiopurity analysis	21
<i>General Biological Experimental</i>	21
<i>Kitasatospora cystargenia</i> culturing, and precursor directed biosynthesis of new to nature bromo-cystargamide	22
Upscaled feeding with selected 6-bromotryptophan at 0.25 mM to 8L culture	30
LC-MSMS analysis of cystargamide and novel cystargamide species	32
Cross-coupling of bromo-cystargamide	85
LC-MSMS analysis of cross-coupled cystargamide	86
NMR spectra for small tryptophan, peptide derivatives and ¹⁹F NMR analysis of cross-coupled cystargamide	

General Chemical Experimental

All reagents were purchased from commercial suppliers and were used without further purification unless otherwise stated. Dry dichloromethane was dried and deoxygenated with an MBraun SPS-800 solvent purification system and the moisture content of the solvent was analysed using a Karl Fischer coulometer (Metler Toledo DL32).

Proton NMR (^1H), carbon NMR (^{13}C), phosphorus NMR (^{31}P) and fluorine NMR (^{19}F) were recorded on a Bruker Ascend 500 (500 MHz), Bruker 500 UltraShield (500 MHz), Bruker Ascend 700 (700 MHz), Bruker 400 UltraShield (400 MHz) or a Bruker UltraShield (300 MHz) spectrometer. Fluorine NMR were also recorded as proton decoupled ($^{19}\text{F}\{^1\text{H}\}$). Phosphorus NMR ($^{31}\text{P}\{^1\text{H}\}$) was recorded as proton decoupled. Using an HSQC experiment with multiplicity editing, the ^{13}C NMR signals were assigned to CH_3 , CH_2 , CH and C . The NMR experiments were carried out in deuteriochloroform (CDCl_3) deuterated water (D_2O), deuterated DMSO (d_6 -DMSO) or deuterated methanol (d_4 -MeOH). The chemical shifts (δ) are quoted in parts per million (ppm). Multiplicities are abbreviated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad for the ^1H NMR, ^{19}F NMR, $^{19}\text{F}\{^1\text{H}\}$ NMR and ^{13}C NMR spectra. Coupling constants are reported in Hertz (Hz).

Flash chromatography was performed using Davisil silica gel LC60A (40-63 micron). Thin layer chromatography (TLC) was performed using aluminium sheets of silica gel 60 F254 and was visualised under a Mineralight model UVGL-58 lamp (254 nm). The plates were developed with acidic methanolic vanillin solutions, ethanolic phosphomolybdic acid solutions or basic potassium permanganate solutions.

High and low resolution mass spectra were recorded at the University of St Andrews on a Waters Micromass LCT time of flight mass spectrometer coupled to a Waters 2975 HPLC system or on an Orbitrap ELOS pro. Optical rotation values were recorded in methanol on a Perkin Elmer Model 341 Polarimeter using a Na/Hal lamp (589 nm) at 20 °C in a 1 dm polarimeter cell and are given in $10^{-1} \text{ deg cm}^2 \text{ g}^{-1}$. Freeze drying was carried out on a Scanvac CoolSafeTM freeze dryer. Microwave reactions were carried out on a Biotage Initiator+.

5-Bromotryptophan **18**, 5-chlorotryptophan **20**, 6-bromotryptophan **21**, 7-bromotryptophan **22** and 7-iodotryptophan **23** were prepared as described previously.¹

HPLC purification was carried out on an XBridge Prep Phenyl 5 μm column (10x250 mm) on a Gilson HPLC system (Gilson 322 pump, Gilson UV/Vis-151 detector, Gilson 402 syringe

pump). UPLC analysis was carried out on a Waters Acquity H-Class UPLC system fitted with an Acquity UPLC BEH C18 column (1.7 μm , 2.1x50 mm).

For purification of the cross coupling products from 5-bromotryptophan **18**, the following program was used: 10% acetonitrile/water for 5 min, 10% acetonitrile/water to 60% acetonitrile/water over 21 minutes, 60% acetonitrile/water to 90% acetonitrile/water over 5 minutes, 90% acetonitrile/water to 10% acetonitrile/water over 5 min, 10% acetonitrile/water for 4 min. Total run time 40 minutes. Flowrate 5 mL/min, detection wavelength 254 nm.

For purification of the cross coupling products from tripeptides **58** and **59**, the following program was used: 10% acetonitrile/water for 5 min, 10% acetonitrile/water to 60% acetonitrile/water over 30 minutes, 60% acetonitrile/water to 90% acetonitrile/water over 5 minutes, 90% acetonitrile/water to 10% acetonitrile/water over 5 min, 10% acetonitrile/water for 4 min. Total run time 50 minutes. Flowrate 5 mL/min, detection wavelength 330 nm.


Purification of selected peptides was carried out on a Biotage Isolera Four using reverse-phase SNAP C18 12 g column cartridges. The purification was carried out using water/methanol on the following gradient: 12 mL/min elution, 2% methanol/water for 1.15 min, 2 \rightarrow 15% methanol/water for 1.15 min, 15% methanol/water for 5.15 min, 15 \rightarrow 95% methanol/water for 15 min, 95% methanol/water for 3.45 min. The collection wavelength was set a 254 nm.

UPLC analysis was carried out on a Waters Acquity H-Class UPLC system.

A 1:1 mixture of water:acetonitrile was freshly prepared before each set of cross coupling reactions. The solvent was degassed by bubbling nitrogen through the solutions for at least 15 minutes, then storing under nitrogen.

The IUPAC names of some compounds were obtained using ChemBioDraw Ultra (version 13.0.2.3012).

Sodium 2'-(Dicyclohexylphosphanyl)-2,6-diisopropyl-(1,1-biphenyl)-4-sulfonate (sXPhos) 12²



Sulfuric acid (1.0 mL) and fuming sulfuric acid (3.0 mL) were added to a suspension of XPhos (433 mg, 0.9 mmol, 1.0 eq) in dry DCM (3 mL) at 0 °C under nitrogen. The reaction was allowed to warm to r.t. and stirred for 24 h. The reaction mixture was cooled to 0 °C and crushed ice (10 g) was added. The reaction mixture was neutralised to pH 7 using sodium hydroxide solution (6 N, ~25 mL). The reaction mixture was extracted with DCM (3 x 50 mL) and the solvent was removed *in vacuo*. The residue was dissolved in cold methanol (20 mL), filtered, the filtrate collected and the solvent removed *in vacuo* to give sodium 2'-(dicyclohexylphosphanyl)-2,6-diisopropyl-(1,1-biphenyl)-4-sulfonate **12** (0.49 g, 100%) as a tan solid; ¹H NMR (500 MHz, *d*₄-MeOH) δ = 0.98 (6H, d, J (H,H)= 6.7 Hz, CH₃), 1.08-1.31 (16H, m, CH₃, CH₂), 1.55-1.89 (12H, m, CH, CH₂), 2.45-2.50 (2H, m, CH), 7.11-7.13 (1H, m, ArH), 7.38-7.47 (2H, m, ArH), 7.65-7.69 (3H, m, ArH); ¹³C NMR (125 MHz, *d*₄-MeOH) δ = 23.1 (CH₃), 25.9 (CH₃), 27.5 (CH₂), 28.3 (d, J (C,P)= 8.9 Hz, CH₂), 28.5 (d, J (C,P)= 11.4 Hz, CH₂), 30.6 (d, J (C,P)= 12.0 Hz, CH₂), 31.9 (CH), 32.3 (d, J (C,P)= 16.1 Hz, CH₂), 35.6 (d, J (C,P)= 15.4 Hz, CH), 121.2 (CH), 128.0 (CH), 129.1 (CH), 132.3 (d, J (C,P)= 6.1 Hz, CH), 133.8 (CH), 137.2 (d, J (C,P)= 17.6 Hz, C), 142.7 (C), 145.5 (C), 147.5 (C), 147.7 (C), 148.3 (C); ³¹P{¹H} NMR (162 MHz, *d*₄-MeOH) δ = -11.91 (1P, s); MS (ESI) 513 (100) [M-Na]⁻; HRMS: *m/z* calcd for C₃₀H₄₂O₃P₁S₁ [M-Na]⁻: 513.2598; found: 513.2596.

Standard Reaction Procedure of 5-bromoindole 15 under reflux:

5-Bromoindole **15** (20 mg, 0.1 mmol, 1.0 eq), *bis*(acetonitrile)dichloropalladium (II) (variable, see Table 1 in main text), sXPhos **12** (variable, see Table 1 in main text) and cesium carbonate (81 mg, 0.26 mmol, 2.5 eq) were added to a flask fitted with a reflux condenser under nitrogen. Degassed water/acetonitrile (1:1, 2 mL) was added to the flask, followed by the liquid alkyne substrate (variable, see Table 1 in main text). The reaction mixture was heated at 100 °C for 18 h. The reaction mixture was then cooled to r.t.

For analysis of the reaction conversions, 0.2 mL of reaction mixture was removed from the well-stirred reaction mixture and the solvent was removed *in vacuo*. The residue was dissolved in *d*₄-MeOH (0.7 mL) and analysed by ¹H NMR.

Microwave Reaction Procedure of 5-bromoindole 15:

5-Bromoindole **15** (20 mg, 0.1 mmol, 1.0 eq), *bis*(acetonitrile)dichloropalladium (II) (1.3 mg, 10 μmol, 5 mol%), sXPhos **12** (8 mg, 30 μmol, 15 mol%) and cesium carbonate (81 mg, 0.26 mmol, 2.5 eq) were added to a microwave tube, which was then fitted with a suba seal. The flask was evacuated and flushed with nitrogen three times. Degassed water/acetonitrile (1:1, 2 mL) and acetonitrile (1.0 mL) were added to the microwave tube, followed by the liquid alkyne substrate (33 μL, 0.3 mmol, 3.0 eq). The tube was sealed and heated at 100 °C for 2 h using a microwave.

For analysis of the reaction conversion, 0.2 mL of reaction mixture was removed from the well-stirred microwave tube and the solvent was removed *in vacuo*. The residue was dissolved in *d*₄-MeOH (0.7 mL) and analysed by ¹H NMR.

Standard Microwave Reaction Procedure for Tryptophans:


The halo-tryptophan obtained from our previously reported procedure¹ (28 mg, 0.1 mmol, 1.0 eq for bromotryptophans, 33 mg 0.1 mmol, 1.0 eq for 7-iodotryptophan), *bis*(acetonitrile)dichloropalladium (II) (1.3 mg, 10 μmol, 5 mol%), sXPhos **12** (8 mg, 30 μmol, 15 mol%), (in the reaction with 4-cyanophenylacetylene **25**, 3.0 eq of the solid alkyne was also added at this stage) and cesium carbonate (81 mg, 0.26 mmol, 2.5 eq) were added to a microwave tube, which was then fitted with a suba seal. The flask was evacuated and flushed with nitrogen three times. Degassed water:acetonitrile (1:1, 2.0 mL) were added to the

microwave tube, followed by the liquid alkyne substrate (0.3 mmol, 3.0 eq). The tube was sealed and heated at 100 °C for 2 h using a microwave.

For analysis of the reaction conversions, 0.2 mL of reaction mixture was removed from the well-stirred microwave tube and the solvent was removed *in vacuo*. The residue was dissolved in *d*₄-MeOH (0.7 mL) and analysed by ¹H NMR.

For purification of specified reactions, the reaction mixture was cooled to r.t. and diluted with water (6.0 mL). The reaction mixture was centrifuged (13,000 rpm, 16060 g, for 5 min). The ultrafiltrate was collected and purified by HPLC purification, as described above, in 1 mL injections. The appropriate HPLC fractions (generally eluted at 18-20 minutes) were collected and the solvent removed *in vacuo*. The residue was re-suspended in water (50-100 mL) and lyophilised to give the product.


(*S*)-2-Amino-3-(5-(phenylethynyl)-1*H*-indol-3-yl)propanoic acid **19**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and phenylacetylene **16** (33 μ L, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-(5-(phenylethynyl)-1*H*-indol-3-yl)propanoic acid **19** (29.4 mg, 97%) as a fluffy, white solid; $[\alpha]_D -41.1^\circ$ (c 0.27, MeOH); ¹H NMR (500 MHz, *d*₄-MeOH) δ = 3.03 (1H, dd, $J(\text{H,H})$ = 14.1, 8.4 Hz, CH_AH_B), 3.37 (1H, d, $J(\text{H,H})$ = 14.4 Hz, CH_AH_B), 3.68 (1H, bs, CH), 7.22 (1H, s, ArH), 7.26 (1H, dd, $J(\text{H,H})$ = 8.4, 1.5 Hz, ArH), 7.29-7.37 (4H, m, ArH), 7.48-7.51 (2H, m, ArH), 7.96 (1H, d, $J(\text{H,H})$ = 0.7 Hz, ArH); ¹³C NMR (125 MHz, *d*₄-MeOH) δ = 31.0 (CH₂), 57.5 (CH), 87.4 (C), 92.5 (C), 111.9 (C), 112.5 (CH), 114.6 (C), 123.8 (CH), 125.6 (C), 125.96 (CH), 126.02 (CH), 128.7 (CH), 128.9 (C), 129.4 (CH), 132.2 (CH), 138.0 (C), 179.3 (CO); MS (ESI) 305 (100) $[\text{M}+\text{H}]^+$, 288 (80); HRMS: m/z calcd for C₁₉H₁₇N₂O₂ $[\text{M}+\text{H}]^+$: 305.1285; found: 305.1273.

The reaction was repeated to give 22.0 mg (73%) and 21.4 mg (70%) of the expected product **19** to give an average yield of 80% over three reactions.


(*S*)-2-Amino-3-5-((3-fluorophenyl)ethynyl)-1*H*-indol-3-yl)propanoic acid **36**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 3-fluorophenylacetylene **24** (34 μ L, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-5-((3-fluorophenyl)ethynyl)-1*H*-indol-3-yl)propanoic acid **36** (32.2 mg, 100%) as a white solid; $[\alpha]_D^{25} -37.7^\circ$ (c 0.26, MeOH); $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) $\delta = 3.14$ (1H, dd, $J(\text{H,H}) = 15.0, 8.9$ Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.45-3.49 (1H, m, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.81 (1H, dd, $J(\text{H,H}) = 8.9, 3.8$ Hz, CH), 7.07 (1H, ddd, $J(\text{H,H}) = 9.0, 2.7$ Hz, $J(\text{H,F}) = 0.6$ Hz, ArH), 7.22 (1H, ddd, $J(\text{H,H}) = 2.7, 1.0$ Hz, $J(\text{H,F}) = 9.6$ Hz, ArH), 7.25 (1H, s, ArH), 7.28-7.33 (2H, m, ArH), 7.35-7.40 (2H, m, ArH), 8.00 (1H, d, $J(\text{H,H}) = 0.6$ Hz, ArH); $^{13}\text{C NMR}$ (125 MHz, d_4 -MeOH) $\delta = 29.0$ (CH_2), 56.9 (CH), 86.3 (C), 93.5 (C), 110.6 (C), 112.7 (CH), 114.3 (C), 115.8 (d, $J(\text{C,F}) = 21.4$ Hz, CH), 118.6 (d, $J(\text{C,F}) = 22.9$ Hz, CH), 123.8 (C), 126.2 (CH), 126.4 (CH), 127.6 (d, $J(\text{C,F}) = 9.5$ Hz, C), 128.3 (d, $J(\text{C,F}) = 2.7$ Hz, CH), 128.7 (C), 131.3 (d, $J(\text{C,F}) = 8.8$ Hz, C), 138.2 (C) 164.0 (d, $J(\text{C,F}) = 244.8$ Hz, CF), 175.7 (CO); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, d_4 -MeOH) $\delta = -115.34$ (1F, s); $^{19}\text{F NMR}$ (376 MHz, d_4 -MeOH) $\delta = -115.31$ (1F, dddd, $J(\text{H,F}) = 9.6, 8.5, 5.8, 0.6$ Hz); MS (ESI) 323 (60) $[\text{M}+\text{H}]^+$, 306 (50), 196 (80), 118 (100); HRMS: m/z calcd for $\text{C}_{19}\text{H}_{16}\text{F}_1\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 323.1190; found: 323.1190.

The reaction was repeated to give 32.2 mg (100%) and 28.9 mg (90%) of the expected product **36** to give an average yield of 97% over three reactions.

(*S*)-2-Amino-3-5-((4-cyanophenyl)ethynyl)-1*H*-indol-3-yl)propanoic acid **39**




Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 4-cyanophenylacetylene **25** (38 mg, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-5-((3-cyanophenyl)ethynyl)-1*H*-indol-3-yl)propanoic acid **39** (26.1 mg, 79%) as a brown solid; $[\alpha]_D^{25} -37.7^\circ$ (c 0.30, MeOH); $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) $\delta = 3.19$ (1H, dd, $J(\text{H,H}) = 15.2, 8.7$ Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.50 (1H, dd, $J(\text{H,H}) = 15.2, 4.0$ Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.81 (1H, dd, $J(\text{H,H}) = 8.7, 4.0$ Hz, CH), 7.28 (1H, s, ArH), 7.32 (1H, dd, $J(\text{H,H}) = 8.4, 1.3$ Hz, ArH), 7.40 (1H, d, $J(\text{H,H}) = 8.4$ Hz,

ArH), 7.65-7.66 (2H, m, ArH), 7.72-7.74 (2H, m, ArH), 8.03 (1H, s, ArH); ^{13}C NMR (125 MHz, d_4 -MeOH) δ = 28.4 (CH₂), 56.7 (CH), 86.4 (C), 97.3 (C), 110.4 (C), 111.8 (C), 112.8 (CH), 113.8 (C), 119.5 (C), 124.2 (CH), 126.3 (CH), 126.7 (C), 128.6 (C), 130.6 (C), 132.9 (CH), 133.4 (CH), 138.5 (C), 174.6 (CO); MS (ESI) 330 (100) [M+H]⁺, 313 (90), 196 (90), 118 (100); HRMS: m/z calcd for C₂₀H₁₆N₃O₂ [M+H]⁺: 330.1237; found: 330.1237.

The reaction was repeated to give 25.9 mg (79%) and 26.0 mg (79%) of the expected product **39** to give an average yield of 79% over three reactions.


(*S*)-2-Amino-3-(5-(thiophen-3-ylethynyl)-1*H*-indol-3-yl)propanoic acid **42**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 3-ethynylthiophene **26** (30 μL , 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-(5-(thiophen-3-ylethynyl)-1*H*-indol-3-yl)propanoic acid **42** (28.1 mg, 91%) as a fluffy, white solid; $[\alpha]_{\text{D}} -47.8^{\circ}$ (c 0.23, MeOH); ^1H NMR (500 MHz, d_4 -MeOH) δ = 3.03 (1H, dd, $J(\text{H,H})$ = 12.4, 7.9 Hz, CH_AH_B), 3.37 (1H, d, $J(\text{H,H})$ = 14.3 Hz, CH_AH_B), 3.68 (1H, bs, CH), 7.18 (1H, dd, $J(\text{H,H})$ = 5.0, 1.1 Hz, ArH), 7.21 (1H, s, ArH), 7.23 (1H, dd, $J(\text{H,H})$ = 8.4, 1.3 Hz, ArH), 7.33 (1H, d, $J(\text{H,H})$ = 8.4 Hz, ArH), 7.42 (1H, dd, $J(\text{H,H})$ = 5.0, 3.0 Hz, ArH), 7.54 (1H, dd, $J(\text{H,H})$ = 3.0, 1.1 Hz, ArH), 7.94 (1H, s, ArH); ^{13}C NMR (125 MHz, d_4 -MeOH) δ = 30.9 (CH₂), 57.5 (CH), 82.6 (C), 91.7 (C), 111.8 (C), 112.5 (CH), 114.6 (C), 123.6 (CH), 124.5 (C), 125.9 (CH), 126.0 (CH), 126.4 (CH), 128.54 (CH), 128.9 (C), 130.8 (CH), 137.9 (C), 179.5 (CO); MS (ESI) 311 (100) [M+H]⁺, 294 (90); HRMS: m/z calcd for C₁₇H₁₅N₂O₂S₁ [M+H]⁺: 311.0849; found: 311.0837.

The reaction was repeated to give 19.8 mg (64%) and 22.1 mg (71%) of the expected product **42** to give an average yield of 75% over three reactions.


(*S*)-2-Amino-3-(5-(4-hydroxybut-1-yn-1-yl)-1*H*-indol-3-yl)propanoic acid **45**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 3-butyn-1-ol **27** (23 μ L, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-(5-(4-hydroxybut-1-yn-1-yl)-1*H*-indol-3-yl)propanoic acid **45** (21.4 mg, 79%) as a fluffy, white solid; $[\alpha]_D -30.0^\circ$ (c 0.23, MeOH); $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) δ = 2.61 (2H, t, $J(\text{H,H})$ = 6.9 Hz, CH_2), 2.93 (1H, dd, $J(\text{H,H})$ = 14.3, 8.2 Hz, CH_AH_B), 3.26 (1H, dd, $J(\text{H,H})$ = 14.3, 4.3 Hz, CH_AH_B), 3.53-3.56 (1H, m, CH), 3.73 (2H, t, $J(\text{H,H})$ = 7.0 Hz, CH_2), 7.12 (1H, dd, $J(\text{H,H})$ = 8.4, 1.4 Hz, ArH), 7.16 (1H, s, ArH), 7.25 (1H, d, $J(\text{H,H})$ = 8.4 Hz, ArH), 7.80 (1H, s, ArH); $^{13}\text{C NMR}$ (125 MHz, d_4 -MeOH) δ = 24.4 (CH_2), 32.1 (CH_2), 57.9 (CH), 62.1 (CH_2), 84.2 (C), 84.3 (C), 112.2 (CH), 112.5 (C), 115.1 (C), 123.6 (CH), 125.6 (CH), 126.0 (CH), 128.9 (C), 137.6 (C), 181.3 (CO); MS (ESI) 273 (100) $[\text{M}+\text{H}]^+$, 256 (30), 198 (50), 196 (100), 158 (70); HRMS: m/z calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 273.1234; found: 273.1233.

The reaction was repeated to give 17.3 mg (64%) and 27.0 mg (99%) of the expected product **45** to give an average yield of 81% over three reactions.


(*S*)-2-Amino-3-(5-(4-phenylbut-1-yn-1-yl)-1*H*-indol-3-yl)propanoic acid **48**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 4-phenyl-1-butyne **28** (42 μ L, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-(5-(4-phenylbut-1-yn-1-yl)-1*H*-indol-3-yl)propanoic acid **48** (8.9 mg, 27%) as a light brown solid; $[\alpha]_D -24.8^\circ$ (c 0.27, MeOH); $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) δ = 2.67 (2H, t, $J(\text{H,H})$ = 7.5 Hz, CH_2), 2.90 (2H, t, $J(\text{H,H})$ = 7.5 Hz, CH_2), 3.00 (1H, dd, $J(\text{H,H})$ = 14.3, 8.6 Hz, CH_AH_B), 3.33-3.37 (1H, m, CH_AH_B), 3.67 (1H, bs, CH), 7.08 (1H, dd, $J(\text{H,H})$ = 8.3, 1.3 Hz, ArH), 7.17-7.21 (2H, m, ArH), 7.25-7.31 (5H, m, ArH), 7.75 (1H, s, ArH); $^{13}\text{C NMR}$ (125 MHz, d_4 -MeOH) δ = 23.1 (CH_2), 31.2 (CH_2), 37.1 (CH_2), 57.9 (CH), 84.4 (C), 87.4 (C), 112.0 (C), 112.7 (CH), 116.0 (CH), 123.7 (CH), 126.2 (CH), 126.6 (CH), 127.7 (CH), 129.2 (C), 129.8 (CH), 130.1 (CH), 138.1 (C) 142.9 (C), 179.5 (CO); MS (ESI) 333 (100) $[\text{M}+\text{H}]^+$, 316 (60); HRMS: m/z calcd for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 333.1598; found: 333.1591.

The reaction was repeated to give 8.3 mg (25%) and 8.7 mg (26%) of the expected product **48** to give an average yield of 26% over three reactions.


(*S*)-2-Amino-3-(5-(octa-1,7-diyn-1-yl)-1*H*-indol-3-yl)propanoic acid **51**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 1,7-octadiyne **29** (40 μ L, 0.3 mmol, 3.0 eq) gave (*S*)-2-amino-3-(5-(octa-1,7-diyn-1-yl)-1*H*-indol-3-yl)propanoic acid **51** (17.2 mg, 56%) as a tan solid; $[\alpha]_D -23.1^\circ$ (c 0.29, MeOH); $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) δ = 1.68-1.75 (4H, m, CH_2), 2.22-2.27 (3H, CH, CH_2), 2.42-2.45 (2H, m, CH_2), 2.98 (1H, dd, $J(\text{H,H})$ = 14.6, 8.5 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.33-3.35 (1H, m, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.65 (1H, bs, CH), 7.11 (1H, dd, $J(\text{H,H})$ = 8.4, 1.4 Hz, ArH), 7.17 (1H, s, ArH), 7.26 (1H, d, $J(\text{H,H})$ = 8.4 Hz, ArH), 7.28 (1H, s, ArH); $^{13}\text{C NMR}$ (125 MHz, d_4 -MeOH) δ = 18.6 (CH_2), 19.6 (CH_2), 28.9 (CH_2), 29.2 (CH_2), 31.0 (CH_2), 57.5 (CH), 69.7 (CH), 83.5 (C), 84.8 (C), 86.9 (C), 111.6 (C), 112.2 (CH), 115.5 (CH), 123.2 (CH), 125.7 (CH), 126.1 (CH), 128.7 (C) 137.5 (C), 179.4 (CO); MS (ESI) 309 (100) $[\text{M}+\text{H}]^+$, 292 (70); HRMS: m/z calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 309.1598; found: 309.1586.

The reaction was repeated to give 15.0 mg (49%) and 16.0 mg (52%) of the expected product **51** to give an average yield of 52% over three reactions.


(*S*)-2-Amino-3-(3-cyclohexylprop-1-yn-1-yl)-1*H*-indol-3-yl)propanoic acid **54**



Using the standard procedure for tryptophans, 5-bromotryptophan **18** (28 mg, 0.1 mmol, 1.0 eq) and 3-cyclohexyl-1-propyne **30** (43 μ L, 0.3 mmol, 3.0 eq) at 100 $^\circ\text{C}$ for 8 h gave (*S*)-2-amino-3-(3-cyclohexylprop-1-yn-1-yl)propanoic acid **54** (8 mg, ~25%) as a fluffy, white solid that contained the sXPhos **12** ligand as an inseparable impurity; $^1\text{H NMR}$ (500 MHz, d_4 -MeOH) δ = 1.10 (2H, dt, $J(\text{H,H})$ = 12.5, 12.4, 3.1 Hz, CH_2), 1.17-1.43 (2H, m, CH_2), 1.50-1.58 (1H,


m, CH), 1.68-1.84 (2H, m, CH₂), 1.90-1.95 (2H, m, CH₂), 2.29 (2H, d, $J(\text{H,H}) = 6.7$ Hz, CH₂), 2.93 (1H, dd, $J(\text{H,H}) = 14.2, 8.4$ Hz, CH_AH_B), 3.328-3.30 (1H, m, CH_AH_B), 3.59 (1H, s, CH), 7.09 (1H, dd, $J(\text{H,H}) = 8.4, 1.4$ Hz, ArH), 7.16 (1H, s, ArH), 7.25 (1H, d, $J(\text{H,H}) = 8.4$ Hz, ArH), 7.76 (1H, s, ArH); ¹³C NMR (125 MHz, *d*₄-MeOH) $\delta = 27.0$ (CH₂), 27.4 (CH₂), 27.5 (CH₂), 31.7 (CH₂), 33.9 (CH₂), 39.2 (CH), 57.8 (CH), 84.2 (C), 86.1 (C), 112.1 (CH), 115.6 (C), 123.2 (CH), 125.6 (CH), 126.0 (CH), 128.8 (C), 137.4 (C), 147.9 (C), 180.7 (CO); MS (ESI) 325 (100) [M+H]⁺, 308 (60); HRMS: m/z calcd for C₂₀H₂₅N₂O₂ [M+H]⁺: 325.1911; found: 325.1890.

***N*-Boc-7-bromo-*S*-tryptophan 66**



A suspension of 7-bromo-*S*-tryptophan **22** (100 mg, 0.35 mmol, 1.0 eq) and di-*t*-butyl dicarbonate (92 mg, 0.42 mmol, 1.2 eq) in 1,4-dioxane-water (1:1, 2 mL) was cooled to 0 °C. Aqueous KOH (1 M, 0.45 mL, 0.45 mmol, 1.25 eq) was added dropwise. The mixture was stirred for 4 h while warming to room temperature. The reaction was diluted with water (10 mL) and extracted with diethyl ether (2 x 10 mL). The aqueous layer was cooled in an ice-bath and the pH was adjusted to 2 using 1 M HCl. The resultant white suspension was extracted using ethyl acetate (3 x 10 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and the solvent was removed *in vacuo* to give *N*-Boc-7-bromo-*S*-tryptophan **66** (120 mg, 89%) as a white, waxy solid that was used without further purification; ¹H NMR (300 MHz, *d*₄-MeOH) $\delta = 1.37$ (9H, s, CH₃), 3.11 (1H, dd, $J(\text{H,H}) = 14.6, 7.8$ Hz, CH_AH_B), 3.31 (1H, dd, $J(\text{H,H}) = 14.9, 5.1$ Hz, CH_AH_B), 4.43 (1H, dd, $J(\text{H,H}) = 7.8, 5.1$ Hz, CH), 6.94 (1H, d, $J(\text{H,H}) = 7.7$ Hz, ArH), 7.17 (1H, s, ArH), 7.26 (1H, d, $J(\text{H,H}) = 7.5$ Hz, ArH), 7.56 (1H, dd, $J(\text{H,H}) = 7.9, 0.7$ Hz, ArH), 10.55 (1H, bs, NH); ¹³C NMR (125 MHz, *d*₄-MeOH) $\delta = 27.3$ (CH₃), 24.7 (CH₂), 54.4 (CH), 79.2 (C), 104.1 (C), 111.18 (C), 111.23 (C), 117.5 (CH), 119.6 (CH), 123.5 (CH), 124.2 (CH), 124.3 (CH), 129.1 (C), 156.3 (CO), 174.3 (CO); MS (ESI) 407 (100) [M(⁸¹Br)+Na]⁺, 405 (100) [M(⁷⁹Br)+Na]⁺; HRMS: m/z calcd for C₁₆H₁₉BrN₂Na₁O₄ [M(⁷⁹Br)+Na]⁺: 405.0420; found: 405.0415.


7-Bromo-*S*-tryptophan methyl ester hydrochloride 67



Thionyl chloride (290 μ L, 4 mmol, 4.0 eq) was added to a flask containing dry methanol (10 mL) at 0 $^{\circ}$ C under argon. After stirring for 10 min, 7-bromo-*S*-tryptophan **22** (285 mg, 1 mmol, 1.0 eq) was added. The reaction was stirred overnight while allowing it to warm to r.t. The solvent was removed *in vacuo* to give 7-bromo-*S*-tryptophan methyl ester hydrochloride **67** (330 mg, 100%) as an off white hydrochloride salt that was used without further purification.


NMR on the HCl salt (d_6 -DMSO) revealed broad signals. Hence, an analytical sample was obtained by desalting with dilute NaHCO₃ solution and extraction with ethyl acetate. Drying (MgSO₄) and evaporation of the solvent afforded the free base suitable for NMR in CDCl₃; ¹H NMR (400 MHz, CDCl₃) δ = 3.08 (1H, dd, J (H,H)= 14.4, 7.4 Hz, CH_AH_B), 3.27 (1H, ddd, J (H,H)= 14.4, 5.0, 0.7 Hz, CH_AH_B), 3.73 (3H, s, CH₃), 3.85 (1H, dd, J (H,H)= 7.4, 5.0 Hz, CH), 7.03 (1H, d, J (H,H)= 7.8 Hz, ArH), 7.15 (1H, d, J (H,H)= 2.2 Hz, ArH), 7.37 (1H, dd, J (H,H)= 7.7, 0.7 Hz, ArH), 7.58 (1H, d, J (H,H)= 7.9 Hz, ArH), 8.37 (1H, bs, NH); ¹³C NMR (100 MHz, CDCl₃) δ = 30.9 (CH₂), 52.2 (CH₃), 55.1 (CH), 105.0 (C), 112.7 (C), 118.2 (CH), 120.9 (CH), 123.6 (CH), 124.7 (CH), 128.9 (C), 135.1 (C), 175.8 (CO); MS (ESI) 299 (100) [M(⁸¹Br)+H]⁺, 297 (100) [M(⁷⁹Br)+H]⁺, 282 (60); HRMS: m/z calcd for C₁₂H₁₄BrN₂O₂ [M(⁷⁹Br)+H]⁺: 297.0233; found: 297.0228.

***N*-Boc-Ala-Phe-OMe 68**




EDC.HCl (536 mg, 2.8 mmol, 1.2 eq) and HOBT (375mg, 2.8 mmol, 1.2 eq) were added to a microwave tube containing Boc-Ala-OH (440 mg, 2.3 mmol, 1.0 eq) in DMF (4.6 mL). The mixture was stirred for 5 min, then DIPEA (1 mL, 5.8 mmol, 2.5 eq) was added and the reaction mixture was stirred for 10 min. H-Phe-OMe.HCl (500 mg, 2.3 mmol, 1.0 eq) was added in one portion and reaction vial was sealed. The reaction was heated in a microwave reactor at 60 $^{\circ}$ C for 20 min. After cooling r.t., the reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (3 x 10 mL), dilute sodium bicarbonate solution (10 mL) and brine (10 mL), dried over anhydrous MgSO₄ and the solvent removed *in vacuo* to give *N*-Boc-Ala-Phe-OMe

68 (750 mg, 90%) as a white, waxy solid that was used without further purification; ^1H NMR (300 MHz, CDCl_3) δ = 1.28 (3H, d, $J(\text{H,H})$ = 7.0 Hz, CH_3), 1.42 (9H, s, CH_3), 3.05 (1H, dd, $J(\text{H,H})$ = 13.8, 6.3 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.13 (1H, dd, $J(\text{H,H})$ = 13.8, 5.9 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.67 (3H, s, CH_3), 4.18 (1H, bs, CH), 4.83 (1H, q, $J(\text{H,H})$ = 6.2 Hz, CH), 5.27 (1H, bs, NH), 6.83 (1H, bs, NH), 7.03-7.15 (2H, m, ArH), 7.16-7.37 (3H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3) δ = 18.4 (CH_3), 28.8 (CH_3), 37.9 (CH_2), 50.0 (CH), 52.3 (CH_3), 53.3 (CH), 79.9 (C), 127.0 (CH), 128.5 (CH), 129.3 (CH), 135.9 (C), 155.4 (CO), 171.8 (CO), 172.5 (CO).




H-Ala-Phe-OMe.TFA **69**




Water (0.2 mL) and TFA (2 mL) were added to a solution of N -Boc-Ala-Phe-OMe **68** (300 mg, 0.86 mmol, 1.0 eq) in DCM (3 mL) at 0 °C and stirred for 2 h, while warming to r.t. The solvent was removed *in vacuo*. The resulting pale, yellow oil was titrated with ice cold diethyl ether (3 x 5 mL) to give H-Ala-Phe-OMe.TFA **69** (310 mg, 91%) as an off white solid that was used without further purification; ^1H NMR (400 MHz, d_4 -MeOH) δ = 1.50 (3H, d, $J(\text{H,H})$ = 7.1 Hz, CH_3), 3.02 (1H, dd, $J(\text{H,H})$ = 14.0, 9.2 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.23 (1H, dd, $J(\text{H,H})$ = 14.0, 5.4 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.73 (3H, s, CH_3), 3.88 (1H, q, $J(\text{H,H})$ = 7.1 Hz, CH), 4.73 (1H, dd, $J(\text{H,H})$ = 9.2, 5.4 Hz, CH), 7.24 (3H, dt, $J(\text{H,H})$ = 9.4, 3.2 Hz, ArH), 7.36-7.28 (2H, m, ArH).

N -Boc-Trp-(7-Br)-Ala-Phe-OMe **70**




A solution of *N*-Boc-Trp-(7-Br)-OH **66** (220 mg, 0.57 mmol, 1.0 eq), H-Ala-Phe-OMe.TFA **69** (210 mg, 0.57 mmol, 1.0 eq) in DMF (4 mL) was cooled to 0 °C. Solid EDC.HCl (132 mg, 0.7 mmol, 1.2 eq) and HOBT (95 mg, 0.7 mmol, 1.2 eq) were added. The reaction mixture was stirred for 5 min, then DIPEA (0.28 mL, 1.6 mmol, 2.8 eq) was added dropwise. The reaction mixture was stirred for 20 h, while warming to r.t. The reaction mixture was diluted with ethyl acetate (20 mL) and washed successively with water (3 x 10 mL) and brine (10 mL). The combined organic layers were dried over anhydrous MgSO₄ and the solvent was removed *in vacuo*. Purification by column chromatography using silica gel (ethyl acetate:hexanes, 10-90%) gave *N*-Boc-Trp-(7-Br)-Ala-Phe-OMe **70** (300 mg, 85%) as a waxy, white solid; ¹H NMR (300 MHz, *d*₄-MeOH) δ = 1.25 (3H, d, *J*(H,H) = 6.9 Hz, CH₃), 1.35 (9H, s, CH₃), 2.91-3.27 (4H, m, CH₂), 3.66 (3H, s, CH₃), 4.26-4.44 (2H, m, CH, CH), 4.61 (1H, d, *J*(H,H) = 6.0 Hz, CH), 6.92 (1H, t, *J*(H,H) = 7.7 Hz, ArH), 7.13-7.21 (4H, m, ArH), 7.22-7.28 (3H, m, ArH), 7.59 (1H, d, *J*(H,H) = 7.8 Hz, ArH); ¹³C NMR (75 MHz, *d*₄-MeOH) δ = 18.4 (CH₃), 28.4 (CH₃), 28.5 (CH₂), 37.9 (CH₂), 49.0 (CH), 52.5 (CH₃), 53.6 (CH), 55.0 (CH), 80.2 (C), 104.9 (C), 111.8 (C), 118.2 (CH), 128.8 (CH), 124.0 (CH), 124.6 (CH), 127.2 (CH), 128.7 (CH), 128.8 (CH), 129.3 (CH), 134.9 (C), 136.0 (C), 155.6 (CO), 171.6 (CO), 171.8 (CO), 171.9 (CO); MS (ESI) 639 (100) [M(⁸¹Br)+Na]⁺, 637 (100) [M(⁷⁹Br)+Na]⁺, 617 (15) [M(⁸¹Br)+H]⁺, 615 (15) [M(⁷⁹Br)+H]⁺; HRMS: *m/z* calcd for C₂₉H₃₆BrN₄O₆ [M(⁷⁹Br)+H]⁺: 615.1813; found: 615.1799.


H-Trp-(7-Br)-Ala-Phe-OH **59**



A solution of lithium hydroxide (14 mg, 0.6 mmol, 1.5 eq) in water (1 mL) was added to a solution of *N*-Boc-Trp-(7-Br)-Ala-Phe-OMe **70** (250 mg, 0.4 mmol, 10 eq) in 1,4-dioxane-*i*PrOH-water (1:1:0.5, 4 mL) at 0 °C. The reaction mixture was stirred vigorously until all the starting material has been consumed (as determined by TLC analysis). The reaction mixture was diluted with water (2 mL) and quenched by the addition of Amberlyst-120-H⁺ (to pH ~5-6). The resin was filtered and the solvent removed *in vacuo* to give the crude free acid (*N*-Boc-Ala-Phe-Trp-(7-Br)-OH). This intermediate was dissolved in DCM (3 mL) and transferred to a microwave vial. TFA (65 μL, 2 mmol, 5.0 eq) was added and reaction vial was sealed with an aluminium crimp cap. Reaction mixture was heated in a microwave reactor at 60 °C for 40 min. After cooling, the solvent was removed *in vacuo*. The residue was purified using gradient reversed phase chromatography (C-18, 12 g, water-MeOH, 5-95% gradient) to give H-Trp-(7-Br)-Ala-Phe-OH.TFA **59** (190 mg, 78% over 2 steps) as a white solid; ¹H NMR (500 MHz, *d*₄-MeOH) δ = 1.37 (3H, d, *J*(H,H) = 7.1 Hz, CH₃-C5), 3.00-3.03 (1H, dd, *J*(H,H) = 14.0, 8.1 Hz, CH_AH_B-C9), 3.12 (1H, dd, *J*(H,H) = 15.2, 9.0 Hz, CH_AH_B-C2), 3.21 (1H, dd, *J*(H,H) = 14.0, 5.2 Hz, CH_AH_B-C9), 3.36 (1H, dd, *J*(H,H) = 15.2, 5.2 Hz, CH_AH_B-C2), 4.11 (1H, dd, *J*(H,H) = 9.0, 5.2 Hz, CH-C1), 4.41 (1H, q, *J*(H,H) = 7.1 Hz, CH-C4), 4.63 (1H, dd, *J*(H,H) = 8.1, 5.2 Hz, CH-C7), 6.94 (1H, dd, *J*(H,H) = 7.8, 7.7 Hz, ArH-C18), 7.17 (1H, ddd, *J*(H,H) = 4.6, 4.1, 4.1 Hz, ArH-C15), 7.26-7.27 (5H, m, ArH-C11,C12,13), 7.30 (1H, d, *J*(H,H) = 7.5 Hz, ArH-C19), 7.66 (1H, d, *J*(H,H) = 7.9 Hz, ArH-C17); ¹³C NMR (125 MHz, *d*₄-MeOH) δ = 18.3 (CH₃, C5), 28.9 (CH₂, C2), 38.3 (CH₂, C9), 50.5 (CH, C4), 54.6 (CH, C1), 55.3 (CH, C7), 105.8 (C, C20), 109.4 (C, C14), 118.6 (C, C17), 121.5 (CH, C18), 125.5 (CH, C19), 126.9 (CH, C13), 127.8 (CH, C15), 129.5 (CH, C10), 129.9 (C, C16), 130.5 (C, C11), 136.8 (C, C21), 138.4 (C, C10), 169.6 (CO, C3), 174.1 (CO, C6), 174.6 (CO, C8); HRMS: *m/z* calcd for C₂₃H₂₆BrN₄O₄ [M(⁷⁹Br)+H]⁺: 501.1132; found: 501.1132.




N-Boc-Trp-(7-Br)-Phe-OMe 71



A solution of *N*-Boc-Trp-(7-Br)-OH **66** (135 mg, 0.37 mmol, 1.0 eq), H-Phe-OMe.HCl (85 mg, 0.4 mmol, 1.1 eq) in DMF (2 mL) was cooled to 0 °C. Solid EDC.HCl (83 mg, 0.43 mmol, 1.2 eq) and HOBT (58 mg, 0.43 mmol, 1.2 eq) were added. The reaction mixture was stirred for 5 min, then DIPEA (0.19 mL, 1.1 mmol, 3.0 eq) was added dropwise. The reaction mixture was stirred for 16 h, while warming to r.t. The reaction mixture was diluted with ethyl acetate (20 mL) and washed successively with water (3 x 10 mL) and brine (10 mL). The combined organic layers were dried over anhydrous MgSO₄ and the solvent was removed *in vacuo*. Purification by column chromatography using silica gel (MeOH:DCM, 0-10%) gave *N*-Boc-Trp-(7-Br)-

Phe-OMe **71** (194 mg, 97%) as a waxy, white solid; ^1H NMR (300 MHz, d_4 -MeOH) δ = 1.36 (9H, s, CH₃), 2.86-3.06 (3H, m, CH, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.15 (1H, dd, $J(\text{H,H})$ = 14.6, 5.9 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.60 (3H, s, CH₃), 4.35 (1H, t, $J(\text{H,H})$ = 6.7 Hz, CH), 4.62 (1H, t, $J(\text{H,H})$ = 6.7 Hz, CH), 6.93 (1H, t, $J(\text{H,H})$ = 7.7 Hz, ArH), 7.06-7.17 (3H, m, ArH), 7.18-7.28 (4H, m, ArH), 7.57 (1H, d, $J(\text{H,H})$ = 7.8 Hz, ArH); ^{13}C NMR (75 MHz, d_4 -MeOH) δ = 27.3 (CH₃), 27.9 (CH₂), 37.1 (CH₂), 51.3 (CH₃), 53.7 (CH), 55.2 (CH), 79.3 (C), 104.1 (C), 111.0 (C), 117.5 (CH), 119.6 (CH), 123.5 (C), 124.4 (CH), 126.5 (CH), 128.1 (CH), 128.9 (CH), 129.1 (CH), 134.9 (C), 136.4 (C), 156.0 (CO), 171.6 (CO), 172.8 (CO); MS (ESI) 568 (100) [$\text{M}(\text{}^{81}\text{Br})+\text{Na}$]⁺, 566 (100) [$\text{M}(\text{}^{79}\text{Br})+\text{Na}$]⁺, 546 (14), 544 (14); HRMS: m/z calcd for C₂₉H₃₆BrN₄O₆ [$\text{M}(\text{}^{79}\text{Br})+\text{H}$]⁺: 544.1442; found: 544.1431.

N*-Boc-Ala-Trp-(7-Br)-Phe-OMe **72*




Water (0.1 mL) and TFA (1 mL) were added to a solution of *N*-Boc-Trp-(7-Br)-Phe-OMe **71** (190 mg, 0.34 mmol, 1.0 eq) in DCM (2 mL) at 0 °C. The reaction mixture was stirred for 2 h, while warming to r.t. The solvent was removed *in vacuo*. The resultant pale yellow oil was triturated with cold diethyl ether (3 x 5 mL) to afford H-Trp-(7-Br)-Phe-OMe.TFA as a white foam.

A solution of H-Trp-(7-Br)-Phe-OMe.TFA (190 mg, 0.34 mmol, 1.0 eq) and *N*-Boc-Ala-OH (70 mg, 0.37 mmol, 1.1 eq) in DCM:DMF (1:1, 4 mL) was cooled to 0 °C. EDC.HCl (78 mg, 0.4 mmol, 1.2 eq) and HOBT (54 mg, 0.4 mmol, 1.2 eq) were added to the reaction mixture. DIPEA (0.2 mL, 1.2 mmol, 3.5 eq) was added dropwise and the reaction mixture was warmed to r.t. and stirred for 16 h. The reaction mixture was diluted with ethyl acetate (20 mL) and washed successively with water (3 x 10 mL) and brine (10 mL). The combined organic layers were dried over anhydrous MgSO₄ and the solvent was removed *in vacuo* to give *N*-Boc-Ala-Trp-(7-Br)-Phe-OMe **72** (190 mg, 85% over 2 steps) as a waxy, white solid that was used without further purification; ^1H NMR (500 MHz, d_6 -DMSO) δ = 1.07 (3H, d, $J(\text{H,H})$ = 7.1 Hz, CH₃), 1.35 (9H, s, CH₃), 2.88-2.97 (2H, m, $\text{CH}_\text{A}\text{H}_\text{B}$, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.00 (1H, dd, $J(\text{H,H})$ = 13.7, 6.1 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.07 (1H, dd, $J(\text{H,H})$ = 14.7, 5.6 Hz, $\text{CH}_\text{A}\text{H}_\text{B}$), 3.56 (3H, s, CH₃), 3.86-4.00 (1H,


m, CH), 4.46 (1H, t, $J(\text{H,H})= 7.2$ Hz, CH), 4.52-4.62 (1H, m, CH), 6.89 (1H, d, $J(\text{H,H})= 7.6$ Hz, ArH), 6.93 (1H, t, $J(\text{H,H})= 7.7$ Hz, ArH), 7.13-7.22 (4H, m, ArH), 7.23-7.31 (3H, m, ArH), 7.58 (1H, d, $J(\text{H,H})= 7.8$ Hz, ArH); ^{13}C NMR (125 MHz, d_6 -DMSO) $\delta = 18.3$ (CH₃), 28.1 (CH₂), 28.5 (CH₃), 37.0 (CH₂), 50.0 (CH), 52.2 (CH₃), 53.0 (CH), 54.0 (CH), 78.7 (C), 104.3 (C), 111.3 (C), 118.4 (CH), 120.1 (CH), 123.8 (CH), 125.3 (CH), 127.0 (CH), 128.7 (C), 129.3 (CH), 129.5 (CH), 134.4 (C), 137.2 (C), 155.4 (CO), 171.5 (CO), 172.0 (CO), 172.8 (CO); MS (ESI) 639 (100) $[\text{M}(\text{}^{81}\text{Br})+\text{Na}]^+$, 637 (100) $[\text{M}(\text{}^{79}\text{Br})+\text{Na}]^+$, 617 (15) $[\text{M}(\text{}^{81}\text{Br})+\text{H}]^+$, 615 (15) $[\text{M}(\text{}^{79}\text{Br})+\text{H}]^+$; HRMS: m/z calcd for C₂₉H₃₆Br₁N₄O₆ $[\text{M}(\text{}^{79}\text{Br})+\text{H}]^+$: 615.1813; found: 615.1800.

H-Ala-Trp-(7-Br)-Phe-OH **58**



Following the procedure reported for **59**, *N*-Boc-Ala-Trp-(7-Br)-Phe-OMe **72** (170 mg, 0.27 mmol, 1.0 eq) gave H-Ala-Trp-(7-Br)-Phe-OH **58** (120 mg, 72% over 2 steps) as a white solid; ^1H NMR (500 MHz, d_4 -MeOH) $\delta = 1.37$ (3H, d, $J(\text{H,H})= 7.1$ Hz, CH₃-C5), 3.00-3.03 (1H, dd, $J(\text{H,H})= 14.0, 8.1$ Hz, CH_AH_B-C9), 3.12 (1H, dd, $J(\text{H,H})= 15.2, 9.0$ Hz, CH_AH_B-C2), 3.21 (1H, dd, $J(\text{H,H})= 14.0, 5.2$ Hz, CH_AH_B-C9), 3.36 (1H, dd, $J(\text{H,H})= 15.2, 5.2$ Hz, CH_AH_B-C2), 4.11 (1H, dd, $J(\text{H,H})= 9.0, 5.2$ Hz, CH-C1), 4.41 (1H, q, $J(\text{H,H})= 7.1$ Hz, CH-C4), 4.63 (1H, dd, $J(\text{H,H})= 8.1, 5.2$ Hz, CH-C7), 6.94 (1H, dd, $J(\text{H,H})= 7.8, 7.7$ Hz, ArH-C18), 7.17 (1H, ddd, $J(\text{H,H})= 4.6, 4.1, 4.1$ Hz, ArH-C15), 7.26-7.27 (5H, m, ArH-C11,C12,13), 7.30 (1H, d, $J(\text{H,H})= 7.5$ Hz, ArH-C19), 7.66 (1H, d, $J(\text{H,H})= 7.9$ Hz, ArH-C17); ^{13}C NMR (125 MHz, d_4 -MeOH) $\delta = 18.3$ (CH₃, C5), 28.9 (CH₂, C2), 38.3 (CH₂, C9), 50.5 (CH, C4), 54.6 (CH, C1), 55.3 (CH, C7), 105.8 (C, C20), 109.4 (C, C14), 118.6 (C, C17), 121.5 (CH, C18), 125.5 (CH, C19), 126.9 (CH, C13), 127.8 (CH, C15), 129.5 (CH, C10), 129.9 (C, C16), 130.5 (C, C11), 136.8 (C, C21), 138.4 (C, C10), 169.6 (CO, C3), 174.1 (CO, C6), 174.6 (CO, C8); HRMS: m/z calcd for C₂₃H₂₆Br₁N₄O₄ $[\text{M}(\text{}^{79}\text{Br})+\text{H}]^+$: 501.1132; found: 501.1128.


((*S*)-2-((*S*)-2-Aminopropanamido)-3-(7-((3-fluorophenyl)ethynyl)-1*H*-indol-3-yl)propanoyl)-L-phenylalanine **60**



((*S*)-2-((*S*)-2-Aminopropanamido)-3-(7-bromo-1*H*-indol-3-yl)propanoyl)-L-phenylalanine **58** (4.0 mg, 8 μ mol, 1.0 eq), sXPhos **12** (0.6 mg, 1.2 μ mol, 15 mol%) and CsCO₃ (6.0 mg, 20 μ mol, 2.5 eq) were added to a microwave tube and flushed with nitrogen. The microwave tube was sealed. A stock solution of *bis*(acetonitrile)dichloropalladium (II) (0.8 mg, 4 μ mol, 0.5 eq) in degassed H₂O:CH₃CN (1:1, 1.0 mL) was prepared. The catalyst stock solution (0.1 mL, 0.4 μ mol, 5 mol%) was injected into the microwave tube, followed by degassed H₂O:CH₃CN (1:1, 0.1 mL). 3-Fluorophenylacetylene **24** (10 μ L, 80 μ mol, 10.0 eq) was then injected into the microwave tube. The reaction mixture was well stirred, then heated at 100 °C for 2 h in a microwave. The reaction mixture was cooled to r.t. and diluted to 3 mL with H₂O:CH₃CN (9:1). The reaction mixture was centrifuged (13,000 rpm, 16060 g, 5 min) and the ultrafiltrate was collected and purified by HPLC purification as described above and lyophilised to give ((*S*)-2-((*S*)-2-aminopropanamido)-3-(7-((3-fluorophenyl)ethynyl)-1*H*-indol-3-yl)propanoyl)-L-phenylalanine **60** (2.0 mg, 47%) as a white solid; ¹H NMR (500 MHz, *d*₄-MeOH) δ = 1.24 (3H, d, *J*(H,H) = 6.9 Hz, CH₃-C2), 3.04 (1H, dd, *J*(H,H) = 13.5, 6.1 Hz, CH_AH_B-C8), 3.08 (1H, dd, *J*(H,H) = 14.6, 9.0 Hz, CH_AH_B-C13), 3.20 (1H, dd, *J*(H,H) = 13.5, 4.9 Hz, CH_AH_B-C8), 3.30-3.38 (1H, dd, *J*(H,H) = 14.6, 4.9 Hz, CH_AH_B-C13), 3.48 (1H, q, *J*(H,H) = 6.9 Hz, CH-C1), 4.45 (1H, dd, *J*(H,H) = 6.1, 4.9 Hz, CH-C6), 4.66 (1H, dd, *J*(H,H) = 9.0, 4.9 Hz, CH-C4), 7.06 (1H, dd, *J*(H,H) = 7.7, 7.6 Hz, ArH-C18), 7.10-7.21 (8H, m, ArH-C10,C11,C12,C15,C25), 7.30 (1H, dd, *J*(H,H) = 7.4, 0.7 Hz, ArH-C19), 7.38-7.44 (2H, m, ArH-C27,C28), 7.43-7.46 (1H, m, ArH-C29), 7.71 (1H, dd, *J*(H,H) = 8.0, 0.9 Hz, ArH-C17)- NOTE- the proton signal at 3.30-3.38 was obscured by the residual *d*₄-MeOH solvent peak, the position of the signal was determined by the 2D NMR experiments, with the coupling constants determined from the coupling constants of the protons on C4 and C13; ¹³C NMR (125 MHz, *d*₄-MeOH) δ = 19.9 (CH₃, C2), 28.8 (CH₂, C13), 39.0 (CH₂, C8), 51.0 (CH, C1), 55.7 (CH, C4), 57.2 (CH, C6), 88.0 (C, C22), 92.4 (C, d, *J*(C,F) = 3.2 Hz, C23), 106.9 (C, C20), 112.1 (C, C14, C16), 116.3 (CH, d, *J*(C,F) = 21.8 Hz, C25), 119.0 (CH, d, *J*(C,F) = 23.1 Hz, C27), 121.0 (CH, C17), 125.5

(CH, C15), 126.3 (CH, C19), 127.0 (C, C24), 127.3 (CH, C12), 128.6 (CH, d, $J(\text{C},\text{F})= 2.8$ Hz, C29), 129.1 (CH, C10), 129.3 (C, C16), 130.8 (CH, C11), 131.4 (CH, d, $J(\text{C},\text{F})= 8.8$ Hz, C28), 138.2 (C, C21), 139.2 (C, C9), 164.0 (CF, d, $J(\text{C},\text{F})= 244.4$ Hz, C26), 172.6 (CO, C5), 176.7 (CO, C3), 177.3 (CO, C7); $^{19}\text{F}\{^1\text{H}\}$ NMR (376 MHz, d_4 -MeOH) $\delta = -115.2$ (1F, s); ^{19}F NMR (470 MHz, d_4 -MeOH) $\delta = -115.2$ (1F, ddd, $J(\text{H},\text{F})= 9.5, 9.1, 5.6$ Hz); MS (ESI) 541 (100) $[\text{M}+\text{H}]^+$; HRMS: m/z calcd for $\text{C}_{31}\text{H}_{30}\text{F}_1\text{N}_4\text{O}_4$ $[\text{M}+\text{H}]^+$: 541.2246; found: 541.2221.

((S)-2-Amino-3-(7-((3-fluorophenyl)ethynyl)-1H-indol-3-yl)propanoyl)-L-alanyl-L-phenylalanine 61



Using the same procedure as **60**, ((S)-2-Amino-3-(7-bromo-1H-indol-3-yl)propanoyl)-L-alanyl-L-phenylalanine **59** (4 mg, 8 μmol , 1.0 eq) gave ((S)-2-amino-3-(7-((3-fluorophenyl)ethynyl)-1H-indol-3-yl)propanoyl)-L-alanyl-L-phenylalanine **61** (4.3 mg, 100%) as a white solid; ^1H NMR (500 MHz, d_4 -MeOH) $\delta = 1.15$ (3H, d, $J(\text{H},\text{H})= 7.1$ Hz, CH_3 -C5), 3.00 (1H, dd, $J(\text{H},\text{H})= 13.6, 6.8$ Hz, $\text{CH}_\text{A}\text{H}_\text{B}$ -C9), 3.02 (1H, dd, $J(\text{H},\text{H})= 14.7, 7.3$ Hz, $\text{CH}_\text{A}\text{H}_\text{B}$ -C2), 3.17-3.22 (2H, m, $\text{CH}_\text{A}\text{H}_\text{B}$ -C2,C9), 3.68 (1H, dd, $J(\text{H},\text{H})= 7.3, 5.2$ Hz, CH-C1), 4.29 (1H, q, $J(\text{H},\text{H})= 7.1$ Hz, CH-C4), 4.45 (1H, dd, $J(\text{H},\text{H})= 6.8, 4.9$ Hz, CH-C7), 7.04 (1H, dd, $J(\text{H},\text{H})= 7.7, 7.5$ Hz, ArH-C18), 7.09-7.13 (2H, m, ArH-C15,C25), 7.17-7.20 (5H, m, ArH-C11,C12,C13), 7.31 (1H, d, $J(\text{H},\text{H})= 7.2$ Hz, ArH-C19), 7.38-7.41 (2H, m, ArH-C27,28), 7.43-7.46 (1H, m, ArH-C29), 7.69 (1H, d, $J(\text{H},\text{H})= 7.9$ Hz, ArH-C17); ^{13}C NMR (125 MHz, d_4 -MeOH) $\delta = 18.0$ (CH_3 , C5), 31.4 (CH_2 , C2), 39.1 (CH_2 , C9), 50.6 (CH, C4), 56.5 (CH, C1), 57.2 (CH, C7), 88.0 (C, C22), 92.4 (C, d, $J(\text{C},\text{F})= 3.0$ Hz, C23), 107.0 (C, C20), 111.8 (C, C14, C16), 116.3 (CH, d, $J(\text{C},\text{F})= 21.5$ Hz, C25), 119.0 (CH, d, $J(\text{C},\text{F})= 23.1$ Hz, C27), 119.9 (CH, C18), 121.1 (CH, C17), 125.9 (CH, C13), 126.3 (CH, C19), 127.0 (C, d, $J(\text{C},\text{F})= 9.3$ Hz, C24), 127.3 (CH, C15), 128.6 (CH, d, $J(\text{C},\text{F})= 2.9$ Hz, C29), 129.1 (CH, C11), 130.8 (CH, C12), 131.3 (CH, d, $J(\text{C},\text{F})= 8.8$ Hz, C28), 138.3 (C, C21), 139.3 (C, C10), 163.9 (CF, d, $J(\text{C},\text{F})= 244.8$ Hz, C26), 173.7 (CO, C6), 176.8 (CO, C3), 177.6 (CO, C8); $^{19}\text{F}\{^1\text{H}\}$ NMR (470 MHz, d_4 -MeOH) $\delta = -115.2$ (1F, s); ^{19}F NMR (470 MHz, d_4 -MeOH) $\delta = -115.2$ (1F, ddd, $J(\text{H},\text{F})=$

9.4, 9.1, 5.8 Hz); MS (ESI) 541 (100) [M+H]⁺; HRMS: *m/z* calcd for C₃₁H₃₀F₁N₄O₄ [M+H]⁺: 541.2246; found: 541.2224.

Enantiopurity analysis

The enantiopurity of the cross coupled products was analysed using Marfey's Reagent (1-fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA).

The tryptophan was dissolved in HCl solution (1 M, 10 mg/mL). An Eppendorf tube containing the tryptophan (50 µL), FDAA (1% w/v in actone, 100 µL) and NaHCO₃ solution (1M, 70 µL) was mixed thoroughly and incubated at 37 °C for 1 h. The reaction mixture was diluted (10 µL in 490 µL water) and centrifuged (13,000 rpm, 16060 g, 5 min) before UPLC analysis.

The UPLC analysis was carried out in acetonitrile/0.1% TFA in water at a gradient of 20% acetonitrile to 90% acetonitrile over 4.7 minutes. A 3:1 mixture of L-tryptophan to D-tryptophan was used as a standard. Two blank runs using acetone were conducted between each tryptophan sample. In all of the tryptophans analysed, only a single peak for the L-enantiomer was observed.

General Biological Experimental

Biological reagents and components for media, buffers and stock solutions were purchased from commercial suppliers, used without further purification and stored according to the supplier's instructions. Microorganisms were stored at -80 °C for long and short-term storage. Microorganisms were cultured under sterile conditions using a Faster BH-EN class II vertical laminar airflow cabinet and fermentation media was sterilised at 121 °C for 20 minutes at 1.3 bar in a Boxer Benchtop Denley autoclave prior to use. Alternatively, aqueous solutions of heat labile components were sterilised by passage through a 0.2 µm membrane. Culturing apparatus was sterilised by autoclaving as described above or alternatively, disposable pre-sterilised apparatus was used.

General apparatus: Pipetting of solutions and samples was done using LABNET Biopette autoclavable pipettes. Microbial cultures were incubated in a New Brunswick Scientific Innova 4300 incubator shaker, a New Brunswick Scientific I26 incubator shaker series, or Genlab incubator (static). pH measurements were taken using a Fisherbrand HydruS 300 pH meter. Centrifugation was carried out using a Thermo Scientific IEC CL30R centrifuge.

***Kitasatospora cystargenia* culturing, and precursor directed biosynthesis of new to nature bromo-cystargamide**

Kitasatospora cystargenia NRRL-B16505 was obtained from the USDA agriculture research service culture collection. The strain was fermented in GY medium (10 g/L glucose, 10 g/L yeast extract) for 48 h at 28 °C (as previously reported by Kerr and coworkers)³ and 200 rpm, in an incubator with a 2.54 cm throw. The mycelium from this culture was stored in 20% glycerol at -80 °C.

Small scale feeding experiments

In order to explore whether the halotryptophans could be incorporated too, we carried out small scale feeding experiments with 7, 6 and 5-chlorotryptophan and 7, 6 and 5-bromotryptophan at 0.25 and 1mM to both 4mL cultures in 24 deep well plates and 50mL cultures in 250mL Erlenmeyer flasks. The cultures were extracted and analysed by LCMSMS. Results demonstrated that all of the halotryptophans incorporated into cystargamide, generating new to nature halogenated analogues.

6Br-tryptophan 21 - Feeding at 0.25 mM scale

Detected Cystargamide Species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	5923338	10.0
Linear cystargamide ^[a]	972.4349	3036620	5.1
Cystargamide no hydroxylated ^[b]	938.4294	607443	1.0
(6BrW) Brominated cystargamide no hydroxylated ^[b]	1016.340	122182	0.2
(6Brw) Brominated cystargamide	1032.334	834562	1.4

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **3:1**

Brominated cystargamide species : Brominated linear cystargamide species = **1:0**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **9:1**

Brominated cyclic cystargamide species : Brominated cystargamide no hydroxylated= **7:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	9574644	16.2
(6BrW) Brominated linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	1048.3662	272892	0.5
(6BrW) Brominated linear cystargamide[ALA] ^[a]	1064.3611	1312663	2.2

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

6Br-tryptophan 21 -Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	9135391	10.0
Linear cystargamide ^[a]	972.4349	4175252	4.6
Cystargamide no hydroxylated ^[b]	938.4294	54982	0.1
(6BrW) Brominated cystargamide no hydroxylated ^[b]	1016.340	1035165	1.1
(6BrW) Brominated cystargamide	1032.334	1928082	2.1

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **3:1**

Brominated cystargamide species : Brominated linear cystargamide species = **1:0**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **10.4:1**

Brominated cyclic cystargamide species : Brominated cystargamide no hydroxylated= **2:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	15397915	16.9
Linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	970.4557	60678	0.1
(6Br) Brominated linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	1048.3662	1907165	2.1
(6Br) Brominated linear cystargamide[ALA] ^[a]	1064.3611	2939735	3.2

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

5Br-tryptophan- Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	17929225	10.0
Linear cystargamide ^[a]	972.4349	600331	3.8
Cystargamide no hydroxylated ^[b]	938.4294	70645	0.3
(5BrW) Brominated cystargamide no hydroxylated ^[b]	1016.3400	312674	0.1

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **3:1**

Brominated cystargamide species : Brominated linear cystargamide species = **1:0**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **21:1**

Brominated cyclic cystargamide species : Brominated cystargamide no hydroxylated= **0:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	9536071	10.8
(5BrW) Brominated linear cystargamide[ALA] no hydroxylated ^{[a],[b],[e]}	1048.3662	266591	0.3

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10 [e] MS2 data was not recorded due to interfering masses

7Br-tryptophan-Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	3227118	10.0
Linear cystargamide ^[a]	972.4349	11589642	35.9
Cystargamide no hydroxylated ^[b]	938.4294	225555	0.7
(7BrW) Brominated cystargamide	1032.3349	348435	1.1

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **0.3:1**

Brominated cystargamide species : Brominated linear cystargamide species = **1:0**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **16:1**

Brominated cyclic cystargamide species : Brominated cystargamide no hydroxylated= **1:0**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	26865004	23.2
Linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	970.4557	1320235	1.1
(7BrW) Brominated linear cystargamide[ALA] no hydroxylated ^{[a],[b],[c]}	1048.3662	576202	0.5
(7BrW) Brominated linear cystargamide[ALA] ^{[a],[d]}	1064.3611	2078672	1.8

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10 [e] MS2 data was not recorded due to interfering masses

5CI-tryptophan-Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.424 4	1590311	10.0
Linear cystargamide ^[a]	972.434 9	714633	4.5
Cystargamide no hydroxylated ^[b]	938.429 4	155629	1.0
(5CIW) Chlorinated linear cystargamide no hydroxylated ^{[a],[b]}	990.401	191149	1.2

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **1.93:1**

Chlorinated cystargamide species : Chlorinated linear cystargamide species = **0:1**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **10:1**

Chlorinated cyclic cystargamide species : Chlorinated cystargamide no hydroxylated= **0:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	2719153	17.1
Linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	970.4557	13496	0.1
(5CIW) Chlorinated linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	1004.4167	806781	5.1

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

6Cl-tryptophan-Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	699261	10.0
Linear cystargamide ^[a]	972.4349	1326172	19.0
Cystargamide no hydroxylated ^[b]	938.4294	23596	0.3
(6ClW) Chlorinated cystargamide no hydroxylated ^[b]	972.3905	1277854	18.3
(6ClW) Chlorinated linear cystargamide no hydroxylated ^{[a],[b]}	990.401	1440729	20.6
(6ClW) Chlorinated cystargamide	988.3854	4530292	64.8
(6ClW) Chlorinated linear cystargamide ^[a]	1006.396	7364948	
	0		100.5

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **0.6:1**

Chlorinated cystargamide species : Chlorinated linear cystargamide species = **0.1:1**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **4:1**

Chlorinated cyclic cystargamide species : Chlorinated cystargamide no hydroxylated= **4:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	4926993	70.5
Linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	970.4557	102532	1.5
(6ClW) Chlorinated linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	1004.4167	7641792	109.3
(6ClW) Chlorinated linear cystargamide[ALA] ^[a]	1020.4116	24151097	345.4

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

7Cl-tryptophan-Feeding at 1 mM scale

Detected Cystargamide species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Cystargamide (WT)	954.4244	2106653	10.0
Linear cystargamide ^[a]	972.4349	1291560	6.1
Cystargamide no hydroxylated ^[b]	938.4294	300104	1.4
(7ClW) Chlorinated cystargamide no hydroxylated ^[b]	972.3905	668116	3.2
(7ClW) Chlorinated linear cystargamide no hydroxylated ^{[a],[b]}	990.401	94561	0.4
(7ClW) Chlorinated cystargamide ^[e]	988.3854	5313075	25.2
(7ClW) Chlorinated linear cystargamide ^[a]	1006.396	2059653	9.8

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10 [e] MS2 data was not recorded due to interfering masses

Ratios of the detected cystargamide species:

Cyclic cystargamide species : Linear cystargamide species = **2:1**

Chlorinated cystargamide species : Chlorinated linear cystargamide species = **3:1**

Cyclic cystargamide species : cyclic cystargamide species no hydroxylated= **8:1**

Chlorinated cyclic cystargamide species : Chlorinated cystargamide no hydroxylated= **8:1**

Analysis of the extract by LC-MS also revealed quantities of analogues of cystargamide containing alanine [ALA] instead of glycine. In this case, only linear forms in which the ester bond appeared to have been hydrolysed were detected.

Detected Cystargamide[ALA] species	[M+H] ⁺	Absorbance peak area ^[c]	Ratio compared to Cystargamide (WT) ^[d]
Linear cystargamide[ALA] ^[a]	986.4500	5187247	24.6
Linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	970.4557	654399	3.1
(7ClW) Chlorinated linear cystargamide[ALA] no hydroxylated ^{[a],[b]}	1004.4167	956515	4.5
(7ClW) Chlorinated linear cystargamide[ALA] ^[a]	1020.4116	7761149	36.8

[a] The ester bond appeared to have been hydrolysed [b] That lacked the 5-hydroxy on the tryptophan [c] Average area from the reaction performed in triplicate [d] Calculated as: (Absorbance peak area species/Absorbance peak area cystargamide wild type (WT))*10

Results demonstrated that all of the halotryptophans incorporated into cystargamide, generating new to nature halogenated analogues. As the concentration of tryptophan had no major impacted the amount of halo-cystargamide produced (see tables below) , we selected to scale up of the feeding of 6-bromotryptophan at 0.25 mM .

Scaled up feeding experiment with 6-bromotryptophan

A starter culture was prepared by inoculation of 50 mL GY medium in a 250 mL baffled conical flask with 2 mL glycerol mycelium stock, and fermented for 48 h at 28 °C and 200 rpm in an incubator with a 2.54 cm throw.

Fermentation cultures (8 L) were prepared by inoculating the production medium (0.4 g/L glucose, 0.8 g/L galactose, 0.8 g/L maltose, 1.6 g/L dextrin, 0.8 g/L soya peptone and 0.3 g/L ammonium sulfate, supplemented with 73 mg/L 6-bromotryptophan [0.26 mM] prepared as previously described¹ with starter culture (10% inoculum), and fermented for 72 h at 28 °C and 200 rpm.

The fermentation cultures were centrifuged (6000 rpm, 8980g, 30 min) and the supernatant was extracted with XAD7-HP resin overnight at 4 °C (20 mL resin / L supernatant). The resin was washed liberally with water, after which bound metabolites were eluted in 400 mL volumes each of 100% aqueous methanol. The presence of cystargamide and bromocystargamide was confirmed by UPLC and the extract was fractionated by gel permeation chromatography, using a 200 mL column of Sephadex LH-20 resin in methanol under gravity flow (25-30 cm/h). Cystargamide and bromocystargamide, both in their linear and cyclised forms, eluted between 120 – 180 mL. These fractions were further fractionated by RP-HPLC, using a Waters XBridge Prep Phenyl 10 x 250 mm 5 µm column with an isocratic gradient of 70% aqueous methanol and 0.1% formic acid and a flow rate of 6 mL/min, monitoring UV absorbance at 280 nm. Cystargamide was found to elute at 10.5 minutes, followed by bromocystargamide at 11 minutes. Solvent was removed from fractions using a Genevac centrifugal vacuum concentrator.


Throughout the purification, fractions were analysed by UPLC (95% acetonitrile and 0.1% trifluoroacetic acid with a flow rate of 0.6 ml/min, monitoring between 220 and 400 nm) or by LC-HRMS (XBridge C18 2.1 x 150 mm column, 5-95% 0.1% formic acid/water; acetonitrile, monitoring at 254 and 280 nm, HRMS: m/z calcd for $C_{49}H_{59}BrN_7O_{13}$ $[M+H]^+$: 1034.3349; found: 1032.3321.

The cystargamide and bromocystargamide were produced in linear and cyclic forms.



Extraction and purification resulted in a pure fraction containing 1.0 mg 6-bromocystargamide **9**. By comparison of the absorbance peak areas it could be estimated that the parent unhalogenated cystargamide **62**, a bromo-cystargamide analogue that lacked the 5-hydroxy on the tryptophan **63** and bromocystargamide **9**, were present in an approximate 10:0.2:1.4 ratio.

LC-MSMS data for cystargamide and its derivatives

Natural Cyclic Cystargamide (62)





Chemical Formula: $C_{49}H_{60}N_7O_{13}^+$
Exact Mass: 954.4244




MS2 spectrum and fragment assignment


RB_20151215_CystargamideExtract #1443 RT: 7.54 AV: 1 NL: 5.15E4
 F: ITMS + p ESI d Full ms2 954.42@cid35.00 [250.00-2000.00]




Chemical Formula: $C_{49}H_{58}N_7O_{12}^+$
 Exact Mass: 936.4138




Chemical Formula: $C_{48}H_{57}N_6O_{12}^+$
 Exact Mass: 909.4029




Chemical Formula: $C_{39}H_{48}N_5O_9^+$
 Exact Mass: 730.3447



Chemical Formula: $C_{35}H_{39}N_6O_{10}^+$
 Exact Mass: 703.2722




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
 Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{31}N_2O_4^+$
 Exact Mass: 399.2278


Linear cystargamide



Chemical Formula: $C_{49}H_{62}N_7O_{14}^+$
 Exact Mass: 972.4349


F:\cyst ms data\PP_20150731_26

08/01/15 11:06:57





PP_20150731_26 #1600 RT: 6.79 AV: 1 SB: 40 7.86-8.43 NL: 1.48E5

F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment


PP_20150731_26 #1601 RT: 6.79 AV: 1 NL: 2.59E4
 F: ITMS + c ESI d Full m/z 972.44@ad35.00 [255.00-985.00]



Chemical Formula: $C_{47}H_{57}N_6O_{12}^+$
 Exact Mass: 897.4029




Chemical Formula: $C_{39}H_{50}N_5O_{10}^+$
 Exact Mass: 748.3552





Chemical Formula: $C_{28}H_{40}N_3O_8^+$
 Exact Mass: 546.2810



Natural cystargamide un-hydroxylated




Chemical Formula: $C_{49}H_{60}N_7O_{12}^+$
 Exact Mass: 938.4294




MS2 spectrum and fragment assignment




Chemical Formula: $C_{48}H_{57}N_6O_{11}^+$
Exact Mass: 893.4080




Chemical Formula: $C_{39}H_{48}N_5O_8^+$
Exact Mass: 714.3497



Chemical Formula: $C_{35}H_{39}N_6O_9^+$
 Exact Mass: 687.2773




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
 Exact Mass: 528.2704





Chemical Formula: $C_{23}H_{31}N_2O_4^+$
 Exact Mass: 399.2278


Bromo-cystargamide un-hydroxylated (63)




Chemical Formula: $C_{49}H_{59}BrN_7O_{12}^+$
 Exact Mass: 1016.3400




MS2 spectrum and fragment assignment







Chemical Formula: $C_{48}H_{56}BrN_6O_{11}^+$
Exact Mass: 971.3185




Chemical Formula: $C_{39}H_{47}BrN_5O_8^+$
Exact Mass: 792.2603



Chemical Formula: $C_{35}H_{38}BrN_6O_9^+$
Exact Mass: 765.1878





Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704




Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278



Brominated linear cystargamide un-hydroxylated





Brominated cystargamide (9)




Chemical Formula: $C_{49}H_{59}BrN_7O_{13}^+$
Exact Mass: 1032.3349




MS2 spectrum and fragment assignment




Chemical Formula: $C_{48}H_{56}BrN_6O_{12}^+$
Exact Mass: 987.3134




Chemical Formula: $C_{39}H_{47}BrN_5O_9^+$
Exact Mass: 808.2552



Chemical Formula: $C_{35}H_{38}BrN_6O_{10}^+$
Exact Mass: 781.1827




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278

Linear cystargamide[ALA]




Chemical Formula: $C_{60}H_{68}N_7O_{14}^+$
Exact Mass: 986.4506

File: ms_data\PP_20150731_46

18:16:16

RT: 0.00 - 15.00




NL: 3.89E5
TIC F: FTMS + p ESI Full
ms [150.00-1500.00]
MS PP_20150731_46

NL: 2.18E6
m/z
986.4000-986.5000 F:
FTMS + p ESI Full ms
[150.00-1500.00] MS
PP_20150731_46

PP_20150731_46 #1678 RT: 7.06 AV: 1 SB: 41 7.86-8.43 NL: 2.08E6


F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment


PP_20150731_46 #1673 RT: 7.04 AV: 1 NL: 2.84E5

F: ITMS + c ESI d Full ms2 986.45@cid35.00 [260.00-1000.00]






Chemical Formula: $C_{47}H_{57}N_6O_{12}^+$
 Exact Mass: 897.4029




Chemical Formula: $C_{39}H_{50}N_5O_{10}^+$
 Exact Mass: 748.3552




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
 Exact Mass: 546.2810


Linear cystargamide[ALA] un hydroxylated



Chemical Formula: $C_{50}H_{64}N_7O_{13}^+$
 Exact Mass: 970.4557





PP_20150731_41 #1807 RT: 7.46 AV: 1 SB: 41 7.86-8.43 NL: 1.19E5
F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment


PP_20150731_41 #1809 RT: 7.47 AV: 1 NL: 1.31E4
F: ITMS + c ESI d Full ms 2 970.46 @d35.00 [255.00-985.00]



Chemical Formula: $C_{50}H_{62}N_7O_{12}^+$
Exact Mass: 952.4451




Chemical Formula: $C_{39}H_{50}N_5O_9^+$
Exact Mass: 732.3603





Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704


Brominated linear cystargamide[ALA] un hydroxylated




Chemical Formula: $C_{50}H_{63}BrN_7O_{13}^+$
Exact Mass: 1048.3662




MS2 spectrum and fragment assignment






Chemical Formula: $C_{47}H_{56}BrN_6O_{11}^+$
Exact Mass: 959.3185




Chemical Formula: $C_{39}H_{49}BrN_5O_9^+$
Exact Mass: 810.2708





Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810


Brominated linear cystargamide[ALA]




Chemical Formula: $C_{50}H_{63}BrN_7O_{14}^+$
Exact Mass: 1064.3611




MS2 spectrum and fragment assignment







Chemical Formula: $C_{47}H_{56}BrN_6O_{12}^+$
Exact Mass: 975.3134



Chemical Formula: $C_{39}H_{46}BrN_5O_{10}^+$
Exact Mass: 826.2657




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810





Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278

(5BrW) Brominated cystargamide unhydroxylated





Chemical Formula: $C_{49}H_{59}BrN_7O_{12}^+$
Exact Mass: 1016.3400




MS2 spectrum and fragment assignment


PP_20150731_45 #1856 RT: 8.00 AV: 1 NL: 3.82E3
F: ITMS + c ESI d Full ms2 1016.34@cid35.00 [285.00-2000.00]




Chemical Formula: $C_{48}H_{56}BrN_6O_{11}^+$
Exact Mass: 971.3185



Chemical Formula: $C_{39}H_{47}BrN_5O_8^+$
Exact Mass: 792.2603




Chemical Formula: $C_{35}H_{38}BrN_6O_9^+$
Exact Mass: 765.1878




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278




(5BrW) Brominated linear cystargamide[ALA] un hydroxylated





Chemical Formula: $C_{50}H_{63}BrN_7O_{13}^+$
Exact Mass: 1048.3662





(7-BrW) Brominated cystargamide




Chemical Formula: $C_{49}H_{59}BrN_7O_{13}^+$
Exact Mass: 1032.3349




MS2 spectrum and fragment assignment




Chemical Formula: $C_{48}H_{56}BrN_6O_{12}^+$
 Exact Mass: 987.3134



Chemical Formula: $C_{39}H_{47}BrN_5O_9^+$
 Exact Mass: 808.2552




Chemical Formula: $C_{35}H_{38}BrN_6O_{10}^+$
Exact Mass: 781.1827




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278




(7BrW) Brominated linear cystargamide[ALA] un hydroxylated



Chemical Formula: $C_{50}H_{63}BrN_7O_{13}^+$
Exact Mass: 1048.3662




(6BrW) Brominated linear cystargamide[ALA]



Chemical Formula: $C_{50}H_{63}BrN_7O_{14}^+$
Exact Mass: 1064.3611


RT: 0.00 - 15.02



NL: 7.48E8
 TIC: F: FTMS + p ESI Full
 ms [150.00-1500.00] MS
 PP_20150731_50


NL: 5.33E5
 m/z:
 1064.3000-1064.4000 F:
 FTMS + p ESI Full ms
 [150.00-1500.00] MS
 PP_20150731_50


PP_20150731_50 #1825 RT: 7.36 AV: 1 SB: 43 7.86-8.43 NL: 3.86E5
 F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment

PP_20150731_50 #1818 RT: 7.34 AV: 1 NL: 4.00E3
 F: ITMS + c ESI d Full ms2 1064.36@cid35.00 [280.00-2000.00]






Chemical Formula: $C_{47}H_{56}BrN_6O_{12}^+$
Exact Mass: 975.3134




Chemical Formula: $C_{39}H_{49}BrN_5O_{10}^+$
Exact Mass: 826.2657





Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810


(5CIW) Chlorinated linear cystargamide no hydroxylated




Chemical Formula: $C_{49}H_{61}ClN_7O_{13}^+$
Exact Mass: 990.4010




MS2 spectrum and fragment assignment






Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
 Exact Mass: 915.3690




Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
 Exact Mass: 766.3213




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
 Exact Mass: 546.2810


(5CIW) Chlorinated linear cystargamide[ALA] unhydroxylated



Chemical Formula: $C_{50}H_{63}ClN_7O_{13}^+$
 Exact Mass: 1004.4167




PP_20150731_34 #1753 RT: 7.68 AV: 1 SB: 41 7.86-8.43 NL: 6.84E4
F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment



PP_20150731_34 #1754 RT: 7.69 AV: 1 NL: 3.51E2
F: ITMS + c ESI d Full ms2 1004.42@cid35.00 [265.00-1015.00]





(6CIW) Chlorinated cystargamide un hydroxylated




Chemical Formula: $C_{49}H_{59}ClN_7O_{12}^+$
Exact Mass: 972.3905




MS2 spectrum and fragment assignment




Chemical Formula: $C_{48}H_{56}ClN_6O_{11}^+$
Exact Mass: 927.3690




Chemical Formula: $C_{39}H_{47}ClN_5O_8^+$
Exact Mass: 748.3108



Chemical Formula: $C_{35}H_{38}ClN_6O_9^+$
 Exact Mass: 721.2383




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
 Exact Mass: 528.2704




Chemical Formula: $C_{23}H_{31}N_2O_4^+$
 Exact Mass: 399.2278


(6CIW) Chlorinated linear cystargamide un hydroxylated



Chemical Formula: $C_{49}H_{61}ClN_7O_{13}^+$
 Exact Mass: 990.4010





PP_20150731_38 #1813 RT: 7.47 AV: 1 SB: 43 7.86-8.43 NL: 2.61E5
F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment

PP_20150731_38 #1809 RT: 7.46 AV: 1 NL: 1.61E3
F: ITMS + c ESI d Full ms2 990.40@cid35.00 [260.00-1005.00]







Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
Exact Mass: 915.3690



Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
Exact Mass: 766.3213




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810





Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278


(6CIW) Chlorinated cystargamide





Chemical Formula: $C_{49}H_{59}ClN_7O_{13}^+$
Exact Mass: 988.3854




(6CIW) Chlorinated linear cystargamide




Chemical Formula: $C_{49}H_{61}ClN_7O_{14}^+$
Exact Mass: 1006.3960




MS2 spectrum and fragment assignment







Chemical Formula: $C_{47}H_{56}ClN_6O_{12}^+$
Exact Mass: 931.3639



Chemical Formula: $C_{39}H_{49}ClN_5O_{10}^+$
Exact Mass: 782.3162




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810





Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278


(6CIW) Chlorinated linear cystargamide[ALA] un hydroxylated




Chemical Formula: $C_{50}H_{63}ClN_7O_{13}^+$
Exact Mass: 1004.4167




MS2 spectrum and fragment assignment







Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
Exact Mass: 915.3690



Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
Exact Mass: 766.3213




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810




Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278


(6CIW)-Chlorinated linear cystargamide[ALA]




Chemical Formula: $C_{50}H_{63}ClN_7O_{14}^+$
Exact Mass: 1020.4116




PP_20150731_37 #1774 RT: 7.31 AV: 1 SB: 43 7.86-8.43 NL: 6.76E6
 F: FTMS + p ESI Full ms [150.00-1500.00]




PP_20150731_37 #1760 RT: 7.27 AV: 1 NL: 6.44E3
 F: ITMS + c ESI d Full ms2 1020.41@cid35.00 [270.00-1035.00]







Chemical Formula: $C_{47}H_{56}ClN_6O_{12}^+$
Exact Mass: 931.3639




Chemical Formula: $C_{39}H_{49}ClN_5O_{10}^+$
Exact Mass: 782.3162




Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810



Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
Exact Mass: 915.3690




Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
Exact Mass: 766.3213





Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810


(7CIW) Chlorinated cystargamide unhydroxylated




Chemical Formula: $C_{49}H_{59}ClN_7O_{12}^+$
Exact Mass: 972.3905




MS2 spectrum and fragment assignment







Chemical Formula: $C_{48}H_{56}ClN_6O_{11}^+$
Exact Mass: 927.3690




Chemical Formula: $C_{39}H_{47}ClN_5O_8^+$
Exact Mass: 748.3108



Chemical Formula: $C_{35}H_{38}ClN_6O_9^+$
Exact Mass: 721.2383




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704





Chemical Formula: $C_{23}H_{31}N_2O_4^+$
Exact Mass: 399.2278



(7CIW) Chlorinated linear cystargamide un hydroxylated




Chemical Formula: $C_{49}H_{61}ClN_7O_{13}^+$
Exact Mass: 990.4010




MS2 spectrum and fragment assignment




Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
Exact Mass: 915.3690




Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
Exact Mass: 766.3213



Chemical Formula: $C_{28}H_{40}N_3O_8^+$
 Exact Mass: 546.2810




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
 Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{31}N_2O_4^+$
 Exact Mass: 399.2278

(7CIW) Chlorinated cystargamide




Chemical Formula: $C_{49}H_{59}ClN_7O_{13}^+$
Exact Mass: 988.3854


F:\cyst.ms\data\PP_20150731_41

01/08/2015 16:33:14


RT: 0.00 - 15.02





PP_20150731_41 #1819 RT: 7.51 AV: 1 SB: 41 7.86-8.43 NL: 6.33E5
F: FTMS + p ESI Full ms [150.00-1500.00]




(7CIW) Chlorinated linear cystargamide




Chemical Formula: $C_{49}H_{61}ClN_7O_{14}^+$
 Exact Mass: 1006.3960




MS2 spectrum and fragment assignment







Chemical Formula: $C_{47}H_{56}ClN_6O_{12}^+$
Exact Mass: 931.3639




Chemical Formula: $C_{39}H_{49}ClN_5O_{10}^+$
Exact Mass: 782.3162



Chemical Formula: $C_{28}H_{40}N_3O_8^+$
Exact Mass: 546.2810




Chemical Formula: $C_{28}H_{38}N_3O_7^+$
Exact Mass: 528.2704



Chemical Formula: $C_{23}H_{33}N_2O_4^+$
Exact Mass: 401.2435


(7CIW) Chlorinated linear cystargamide[ALA] unhydroxylated




Chemical Formula: $C_{50}H_{63}ClN_7O_{13}^+$
Exact Mass: 1004.4167

F:\cyst ms data\PP_20150731_41

01/08/2015 16:33:14





PP_20150731_41 #1867 RT: 7.71 AV: 1 SB: 41 7.86-8.43 NL: 1.36E5
F: FTMS + p ESI Full ms [150.00-1500.00]




MS2 spectrum and fragment assignment

PP_20150731_41 #1869 RT: 7.72 AV: 1 NL: 4.90E2
F: ITMS + c ESI d Full ms2 1004.42@cid35.00 [265.00-1015.00]






Chemical Formula: $C_{47}H_{56}ClN_6O_{11}^+$
 Exact Mass: 915.3690




Chemical Formula: $C_{39}H_{49}ClN_5O_9^+$
 Exact Mass: 766.3213



Chemical Formula: $C_{28}H_{40}N_3O_8^+$
 Exact Mass: 546.2810


(7CIW) Chlorinated linear cystargamide[ALA]




Chemical Formula: $C_{50}H_{63}ClN_7O_{14}^+$
Exact Mass: 1020.4116

F:\cyst ms data\PP_20150731_41

01/08/2015 16:33:14





PP_20150731_41 #1715-1787 RT: 7.13-7.38 AV: 24 SB: 41 7.86-8.43 NL: 4.18E5
F: FTMS + p ESI Full ms [150.00-1500.00]



MS2 spectrum and fragment assignment

PP_20150731_41 #1715-1787 RT: 7.28-7.29 AV: 2 NL: 4.78E3
F: ITMS + c ESI d Full ms2 1020.41@cid35.00 [270.00-1035.00]





Cross coupling reaction on Br-Cystargamide

sXPhos **12** (0.6 mg, 1.2 μ mol) and $CsCO_3$ (6.0 mg, 20 μ mol) were added to a microwave tube and flushed with nitrogen. A stock solution of *bis*(acetonitrile)dichloropalladium (II) (0.8 mg, 4 μ mol) in degassed $H_2O:CH_3CN$ (1:1, 100 μ L) was prepared. The catalyst stock solution (10 μ L, 0.4 μ mol) was added to the microwave tube, followed by a solution of the Br-Cystargamide **9** (1 mg) in $H_2O:CH_3CN$ (1:1, 0.2 mL). 3-Fluorophenylacetylene **24** (10 μ L) was then added. The microwave tube was flushed with nitrogen, then sealed. The reaction mixture was heated at 100 °C for 2 h. The reaction mixture was cooled to r.t. A portion of the reaction mixture (0.1 mL) was removed and diluted with $H_2O:CH_3CN$ (1:1, 0.2 mL). Polystyrene supported triphenylphosphine (5 mg) was added the sample was well shaken. The sample was filtered through a plug of cotton wool, then centrifuged (13,000 rpm, 16060 g, 5 min). The reaction mixture (30 μ L) diluted with $H_2O:CH_3CN$ (9:1, 970 μ L) and analysed by LC-MS.


LC-MS analysis showed signals consistent with the product **64** at 1072 $[M+H]^+$, as well as the hydrolysed linear form of the peptide **65** at 1090 $[M+H]^+$.

^{19}F NMR (470 MHz, D_2O) $\delta = -114.05$ (1F, ddd, $J(\text{H,F}) = 9.9, 9.3, 5.7$ Hz), -114.43 (1F, ddd, $J(\text{H,F}) = 9.7, 9.6, 6.3$ Hz); Assignment of ^{19}F NMR signals to the cyclized and linear products respectively is tentative, and based on the observed ratios by LC-MS.


Compound **65** MS (ESI) 1090 (50) $[\text{M}+\text{H}]^+$, 1046 (40), 641 (40), 515 (100), 376 (50); HRMS: m/z calcd for $\text{C}_{57}\text{H}_{65}\text{F}_1\text{N}_7\text{O}_{14}$ $[\text{M}+\text{H}]^+$: 1090.4568; found: 1090.4562;

Compound **64** MS (ESI) 1072 (30) $[\text{M}+\text{H}]^+$, 1028 (20), 635 (40), 567 (20), 421 (60), 376 (100); HRMS: m/z calcd for $\text{C}_{57}\text{H}_{63}\text{F}_1\text{N}_7\text{O}_{13}$ $[\text{M}+\text{H}]^+$: 1072.4462; found: 1072.4464.

Cross Coupled Cyclised Cystargamide (64)



RT: 0.00 - 14.99




NL: 9.68E7
TIC: F: FTMS + p ESI Full
ms [150.00-1500.00]
MS 160217MJC20503


NL: 2.48E5
m/z: 1072.40-1072.50
F: FTMS + p ESI Full ms
[150.00-1500.00] MS
160217MJC20503

160217MJC20503 #678 RT: 7.80 AV: 1 NL: 2.12E5

F: FTMS + p ESI Full ms [150.00-1500.00]



RT: 0.00 - 14.99





NL: 9.68E7
TIC: F: FTMS + p ESI Full
ms [150.00-1500.00]
MS 160217MJC20503

NL: 2.48E5
m/z: 1072.40-1072.50
F: FTMS + p ESI Full ms
[150.00-1500.00] MS
160217MJC20503


160217MJC20503 #679 RT: 7.81 AV: 1 NL: 2.39E3

F: FTMS + c ESI d Full ms2 1072.45@cid35.00 [285.00-1085.00]






Exact Mass: 1027.4248




Exact Mass: 848.3665




Exact Mass: 528.2704


Cross Coupled Linear Cystargamide (65)




RT: 0.00 - 14.99




160217MJC20503 #693 RT: 7.95 AV: 1 NL: 8.51E5
F: FTMS + p ESI Full ms [150.00-1500.00]




RT: 0.00 - 14.99




160217MJC20503 #698 RT: 7.55 AV: 1 NL: 1.91E3
F: ITMS + c ESI d Full ms2 1090.46@cid35.00 [290.00-1105.00]







Exact Mass: 1015.4248



Exact Mass: 866.3771




Exact Mass: 546.2810




Exact Mass: 528.2704

UPLC chromatograms of purified cystargamide (top/black) and the best purified fraction of brominated cystargamide (bottom/blue) used for cross coupling experiment.




	Name	Retention Time	Area	% Area
1	Cystargamide (top chromatogram)	2.128	4619	14.53
2	Brominated cystargamide derivatives (bottom chromatogram)	2.187	27181	85.47

1. D. R. M. Smith, T. Willemse, D. S. Gkotsi, W. Schepens, B. U. W. Maes, S. Ballet and R. J. M. Goss, *Org. Lett.* 2014, **16**, 2622-2625.
2. K. W. Anderson and S. L. Buchwald, *Angew. Chem. Int. Ed.* 2005, **44**, 6173-6177.
3. K. A. Gill, F. Berru , J. C. Arens and R. G. Kerr, *J. Nat. Prod.*, 2014, **77**, 1372-1376.



12
 $^1\text{H NMR}$ (CD_3OD)




Current Data Parameters
 NAME 09092014-37-rjmg-mc410b-A
 EXPNO 10
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20140909
 Time 19.59
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 ID 65536
 SOLVENT MeOD
 NS 8
 DS 2
 SWH 7002.801 Hz
 FIDRES 0.106854 Hz
 AQ 4.6792703 sec
 RG 90.5
 DW 71.400 usec
 DE 11.40 usec
 TE 295.0 K
 D1 1.0000000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 500.1330008 MHz
 NUC1 1H
 P1 10.35 usec
 PLW1 24.0000000 W

F2 - Processing parameters
 SI 65536
 SF 500.1300097 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



12
¹³C NMR (CD₃OD)





Current Data Parameters
 NAME 09092014-37-rjmg-mc410b-A
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20140909
 Time 20.54
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG udeflt
 TD 21424
 SOLVENT MeOD
 NS 800
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 7.96 usec
 TE 295.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 D12 0.0000200 sec
 D20 200.0000000 sec
 TDC 1

----- CHANNEL f1 -----
 SFO1 125.7716224 MHz
 NUC1 13C
 P1 8.90 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 125.0000000 W
 SPNAM[5] Crp60comp.4
 SFOAL5 0.500
 SPOFFS5 0 Hz
 SFWS 15.12800026 W
 SPNAM[8] Crp60,0.5,20.1
 SFOAL8 0.500
 SPOFFS8 0 Hz
 SFWS8 15.12800026 W

----- CHANNEL f2 -----
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 24.0000000 W
 PLW12 0.39015001 W

F2 - Processing parameters
 SI 262144
 SF 125.7576141 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 FC 1.40



Current Data Parameters
 NAME 09052014-11-rjmg-mc410b-N
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20140905
 Time 9.41
 INSTRUM AV400
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 TD 65536
 SOLVENT MeOD
 NS 128
 DS 4
 SWH 64935.066 Hz
 FIDRES 0.990830 Hz
 AQ 0.5046272 sec
 RG 2048
 DW 7.700 usec
 DE 6.50 usec
 TE 297.7 K
 D1 1.50000000 sec
 D11 0.03000000 sec
 TD0 1

----- CHANNEL f1 -----
 NUC1 31P
 P1 15.00 usec
 PL1 3.74 dB
 PL1W 11.00252919 W
 SFO1 162.0444100 MHz

----- CHANNEL f2 -----
 CPDPRG[2] waltz65
 NUC2 1H
 PCPD2 80.00 usec
 PL2 -3.00 dB
 PL12 14.00 dB
 PL13 14.00 dB
 PL2W 19.24057770 W
 PL12W 0.38389999 W
 PL13W 0.38389999 W
 SFO2 400.3020015 MHz

F2 - Processing parameters
 SI 65536
 SF 162.0444100 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40






Current Data Parameters
NAME 02172016-7-rjmg-mc410-A
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160217
Time 23.47
INSTRUM spect
PROBHD 5 mm CFPBBO BB
PULPROG zg30
TD 65536
SOLVENT MeOD
NS 64
DS 2
SWH 7002.801 Hz
FIDRES 0.106854 Hz
AQ 4.6792703 sec
RG 64
DW 71.400 usec
DE 10.95 usec
TE 295.0 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
SFO1 500.1330008 MHz
NUC1 1H
P1 12.50 usec
PLW1 14.00000000 W

F2 - Processing parameters
SI 65536
SF 500.1300097 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00






Current Data Parameters
 NAME 02172016-7-r jmg-mc410-A
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160218
 Time 1.06
 INSTRUM spect
 PROBHD 5 mm CPPBBO BB
 PULPROG udeft
 TD 21424
 SOLVENT MeOD
 NS 1200
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 19.22 usec
 TE 295.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 D12 0.0000000 sec
 D20 200.0000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 125.7716219 MHz
 NUC1 13C
 P1 11.00 usec
 P13 2000.00 usec
 F26 500.00 usec
 PLW1 63.0000000 W
 SPNAM[5] Crp60comp.4
 SPOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 11.64700031 W
 SPNAM[8] Crp60,0.5,20.1
 SPOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 11.64700031 W

----- CHANNEL f2 -----
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 FCPD2 80.00 usec
 PLW2 14.0000000 W
 PLW12 0.3150000 W

F2 - Processing parameters
 SI 262144
 SF 125.7576124 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 FC 1.40




Current Data Parameters
NAME 03112016-6-rjmg-mc410-A
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160312
Time 1.17
INSTRUM spect
PROBHD 5 mm CPPBBO BB
PULPROG zg30
TD 65536
SOLVENT MeOD
NS 64
DS 2
SWH 7002.801 Hz
FIDRES 0.106854 Hz
AQ 4.6792703 sec
RG 64
DW 71.400 usec
DE 10.95 usec
TE 295.0 K
D1 1.00000000 sec
TD0 1


==== CHANNEL f1 =====
SFO1 500.1330008 MHz
NUC1 1H
P1 12.50 usec
PLW1 14.00000000 W

F2 - Processing parameters
SI 65536
SF 500.1300097 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



36

$^{19}\text{F}\{^1\text{H}\}$ NMR (CD_3OD)




Current Data Parameters
 NAME 01262016-1-rjmg-mc410-F
 EXPNO 11
 PRCCNO 1

F2 - Acquisition Parameters
 Date_ 20160126
 Time 19.10
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgfhigqn.3.and
 TD 131072
 SOLVENT MeOD
 NS 64
 DS 4
 SWH 125000.000 Hz
 FIDRES 0.953674 Hz
 AQ 0.5242880 sec
 RG 121.22
 DW 4.000 usec
 DE 6.93 usec
 TE 295.0 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 470.3477405 MHz
 NUC1 19F
 P1 14.60 usec
 PLW1 48.00000000 W


----- CHANNEL f2 -----
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG2 waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 65536
 SF 470.4041892 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



36
¹⁹F NMR (CD₃OD)

-115.28
 -115.30
 -115.30
 -115.32
 -115.32
 -115.33
 -115.34





Current Data Parameters
 NAME 03162016-7-rjmq-mc410-M
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160316
 Time 11.04
 INSTRUM AVII400
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 65536
 SOLVENT MeOD
 NS 64
 DS 4
 SWE 30000.000 Hz
 FIDRES 0.457764 Hz
 AQ 1.0922667 sec
 RG 128
 DW 16.667 usec
 DE 8.37 usec
 TE 294.8 K
 D1 1.0000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 376.4569514 MHz
 NUC1 19F
 P1 15.00 usec
 PLW1 17.00000000 W

F2 - Processing parameters
 SI 65536
 SF 376.4983662 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



36
¹³C NMR (CD₃OD)

- 175.68
- 164.94
- 163.00
- 138.24
- 131.37
- 131.30
- 128.65
- 128.31
- 128.29
- 127.59
- 127.51
- 126.44
- 126.17
- 123.85
- 118.72
- 118.54
- 115.89
- 115.72
- 114.25
- 112.68
- 110.65
- 93.54
- 86.32
- 56.91
- 49.51
- 49.34
- 49.17
- 49.00
- 48.83
- 48.66
- 48.49
- 29.03


Current Data Parameters
NAME 03112016-6-rjmg-mc410-A
EXPNO 11
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160312
Time 3.14
INSTRUM spect
PROBHD 5 mm CFPBBO BB
PULPROG udeflt
TD 21424
SOLVENT MeOD
NS 1800
DS 0
SWH 29761.904 Hz
FIDRES 1.389185 Hz
AQ 0.3599232 sec
RG 128
DW 16.800 usec
DE 19.22 usec
TE 295.0 K
D1 3.00000000 sec
D11 0.03000000 sec
D12 0.00002000 sec
D20 200.00000000 sec
TD0 1

----- CHANNEL f1 -----
SFO1 125.7716219 MHz
NUC1 13C
P1 11.00 usec
P13 2000.00 usec
P26 500.00 usec
FLW1 63.00000000 W
SPNAM[5] Crp60comp.4
SFOAL5 0.500
SPOFFS5 0 Hz
SPW5 11.64700031 W
SPNAM[8] Crp60,0.5,20.1
SFOAL8 0.500
SPOFFS8 0 Hz
SPW8 11.64700031 W

----- CHANNEL f2 -----
SFO2 500.1320005 MHz
NUC2 1H
CPDPRG[2] waltz65
PCPD2 80.00 usec
PLW2 14.00000000 W
PLW12 0.31500000 W

F2 - Processing parameters
SI 262144
SF 125.7576124 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
FC 1.40




Current Data Parameters
 NAME 03142016-29-rjmg-mc410-A
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160314
 Time 19.09
 INSTRUM spect
 PROBHD 5 mm CPPBBO BB
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 64
 DS 2
 SWH 7002.801 Hz
 FIDRES 0.106254 Hz
 AQ 4.6792703 sec
 RG 57
 DW 71.400 usec
 DE 10.95 usec
 TE 295.0 K
 D1 1.00000000 sec
 TD0 1

===== CHANNEL f1 =====
 SFO1 500.1330008 MHz
 NUC1 1H
 P1 12.50 usec
 PLW1 14.00000000 W

F2 - Processing parameters
 SI 65536
 SF 500.1300097 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




Current Data Parameters
 NAME 03142016-29-rjmg-mc410-A
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160314
 Time 20.53
 INSTRUM spect
 PROBHD 5 mm CPPBBO BB
 PULPROG udefr
 TD 21424
 SOLVENT MeOD
 NS 1600
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 19.22 usec
 TE 295.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 125.7716219 MHz
 NUC1 13C
 P1 11.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 63.00000000 W
 SFNAM[5] Crp60comp.4
 SFOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 11.64700031 W
 SFNAM[8] Crp60,0.5,20.1
 SFOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 11.64700031 W

----- CHANNEL f2 -----
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 14.00000000 W
 PLW12 0.31500000 W

F2 - Processing parameters
 SI 262144
 SF 125.7576120 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40




Current Data Parameters
 NAME 03172016-32-rjmg-mc410-F
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160317
 Time 19.05
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 8
 DS 2
 SWH 6996.269 Hz
 FIDRES 0.106755 Hz
 AQ 4.6836395 sec
 RG 121.22
 DW 71.467 usec
 DE 11.38 usec
 TE 295.0 K
 D1 1.00000000 sec
 TDO 1


===== CHANNEL f1 =====
 SF01 499.9329996 MHz
 NUC1 1H
 P1 10.60 usec
 PLW1 16.00000000 W

F2 - Processing parameters
 SI 65536
 SF 499.9300095 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



42

¹³C NMR (CD₃OD)




Current Data Parameters
 NAME 03172016-32-rjmq-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160317
 Time 20.49
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG udef
 TD 21424
 SOLVENT MeOD
 NS 1600
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 121.22
 DW 16.800 usec
 DE 9.36 usec
 TE 295.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 125.7213263 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 85.00000000 W
 SFNAM[5] Crp60comp.4
 SFOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 12.98700047 W
 SFNAM[8] Crp60,0.5,20.1
 SFOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 12.98700047 W

----- CHANNEL f2 -----
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 262144
 SF 125.7073222 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40




Current Data Parameters
 NAME 02252015-18-rjmq-mc410-F
 EXPNO 10
 FROCNQ 1

F2 - Acquisition Parameters
 Date_ 20150225
 Time 22.59
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 8
 DS 2
 SWH 6996.269 Hz
 FIDRES 0.106755 Hz
 AQ 4.6836395 sec
 RG 121.22
 DW 71.467 usec
 DE 11.38 usec
 TE 295.8 K
 D1 1.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SF01 499.9329996 MHz
 NUC1 1H
 P1 10.60 usec
 PLW1 16.00000000 W

F2 - Processing parameters
 SI 65536
 SF 499.9300097 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




Current Data Parameters
 NAME 02252015-18-rjmg-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150225
 Time 23.54
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG udeflt
 ID 21424
 SOLVENT MeCD
 NS 800
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 121.22
 DW 16.800 usec
 DE 9.36 usec
 TE 297.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TDC 1

===== CHANNEL f1 =====
 SFO1 125.7213263 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 85.00000000 W
 SPNAM[5] Crp60comp.4
 SPOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 12.98700047 W
 SPNAM[8] Crp60,0.5,20.1
 SPOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 12.98700047 W

===== CHANNEL f2 =====
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 262144
 SF 125.7073225 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40




Current Data Parameters
 NAME 01202016-5-rjmg-mc410-F
 EXPNO 10
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20160120
 Time 19.04
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 8
 DS 2
 SWH 6996.269 Hz
 FIDRES 0.106755 Hz
 AQ 4.6836395 sec
 RG 121.22
 DW 71.467 usec
 DE 11.38 usec
 TE 295.0 K
 D1 1.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SF01 499.9329996 MHz
 NUC1 1H
 P1 10.60 usec
 PLW1 16.00000000 W

F2 - Processing parameters
 SI 65536
 SF 499.9300096 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



48
¹³C NMR (CD₃OD)




Current Data Parameters
 NAME 01202016-5-rjmg-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160120
 Time 19.59
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG udef
 TD 21424
 SOLVENT MeOD
 NS 800
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 121.22
 DW 16.800 usec
 DE 9.36 usec
 TE 295.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TD0 1


----- CHANNEL f1 -----
 SFO1 125.7213263 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 85.00000000 W
 SFNAM[5] Crp60comp.4
 SFOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 12.98700047 W
 SFNAM[8] Crp60,0.5,20.1
 SFOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 12.98700047 W

----- CHANNEL f2 -----
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 262144
 SF 125.7072585 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40



51
¹H NMR (CD₃OD)




Current Data Parameters
 NAME 07142015-11-rjmg-mc410-M
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150714
 Time 22.42
 INSTRUM AVII400
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 8
 DS 2
 SWE 5605.381 Hz
 FIDRES 0.085531 Hz
 AQ 5.8458114 sec
 RG 128
 DW 89.200 usec
 DE 13.44 usec
 TE 294.9 K
 D1 1.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 400.1324008 MHz
 NUC1 1H
 P1 15.50 usec
 PLW1 12.00000000 W

F2 - Processing parameters
 SI 65536
 SF 400.1300079 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



Current Data Parameters
 NAME 07132015-11-rjmg-mc410-A
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20150713
 Time 21.04
 INSTRUM spect
 PROBHD 5 mm CFPBBO BB
 PULPROG udeft
 TD 21424
 SOLVENT MeOD
 NS 400
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 19.86 usec
 TE 295.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 125.7716219 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 68.00000000 W
 SPNAM[5] Crp60comp.4
 SFOALS 0.500
 SFOFFS5 0 Hz
 SPW5 10.39000034 W
 SPNAM[8] Crp60,0.5,20.1
 SFOALS 0.500
 SFOFFS8 0 Hz
 SPW8 10.39000034 W

----- CHANNEL f2 -----
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 15.00000000 W
 PLW12 0.32633999 W

F2 - Processing parameters
 SI 262144
 SF 125.7576133 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40




Current Data Parameters
NAME 03182D16-14-rjmg-mc410-F
EXFNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160318
Time 21.11
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65536
SOLVENT MeOD
NS 8
DS 2
SWH 6996.269 Hz
FIDRES 0.106755 Hz
AQ 4.6836395 sec
RG 121.22
DW 71.467 usec
DE 11.38 usec
TE 295.0 K
D1 1.00000000 sec
TDO 1


===== CHANNEL f1 =====
SFO1 499.9329996 MHz
NUC1 1H
P1 10.60 usec
PLW1 16.00000000 W


F2 - Processing parameters
SI 65536
SF 499.9300095 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




54

¹H NMR (CD₃OD)





54
¹³C NMR (CD₃OD)



Current Data Parameters
 NAME 03182016-14-rjmg-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160318
 Time 23.20
 INSTRUM spect
 PROBHD 5 mm FAPBO BB/
 PULPROG udef2
 TD 21424
 SOLVENT MeOD
 NS 2000
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 121.22
 DW 16.800 usec
 DE 9.36 usec
 TE 295.0 K
 D1 3.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 D20 200.00000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 125.7213263 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 85.00000000 W
 SFNAM[5] Crp60comp.4
 SFOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 12.98700047 W
 SFNAM[8] Crp60,0.5,20.1
 SFOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 12.98700047 W

----- CHANNEL f2 -----
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 262144
 SF 125.7073227 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40





Current Data Parameters
NAME 03182016-15-rjmg-mc410-F
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160318
Time 23.25
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65536
SOLVENT MeOD
NS 8
DS 2
SWH 6996.259 Hz
FIDRES 0.106755 Hz
AQ 4.6836395 sec
RG 121.22
DW 71.467 usec
DE 11.38 usec
TE 295.0 K
D1 1.00000000 sec
TDO 1


===== CHANNEL f1 =====
SFO1 499.9329996 MHz
NUC1 1H
P1 10.60 usec
PLW1 16.00000000 W

F2 - Processing parameters
SI 65536
SF 499.9300096 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
FC 1.00





58
¹³C NMR (CD₃OD)



172.81
 172.60
 170.80

138.65
 130.59
 130.25
 129.27
 127.56
 125.86
 125.06
 121.12
 118.90
 112.34
 105.61

56.06
 55.64
 50.09
 38.53
 29.04
 17.72




Current Data Parameters
 NAME 03182016-15-rjmg-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160319
 Time_ 0.19
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG udef
 TD 21424
 SOLVENT MeOD
 NS 800
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 121.22
 DW 16.800 usec
 DE 9.36 usec
 TE 295.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 D12 0.0000200 sec
 D20 200.0000000 sec
 TD0 1

===== CHANNEL f1 =====
 SFO1 125.7213263 MHz
 NUC1 13C
 P1 10.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 85.00000000 W
 SPNAM[5] Crp60comp.4
 SPCAL5 0.500
 SPCFFS5 0 Hz
 SPW5 12.98700047 W
 SPNAM[8] Crp60,0.5,20.1
 SPCAL8 0.500
 SPCFFS8 0 Hz
 SPW8 12.98700047 W

===== CHANNEL f2 =====
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 262144
 SF 125.7073220 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40




Current Data Parameters
 NAME 03222016-11-rjmg-mc410-E
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160322
 Time 16.49
 INSTRUM spect
 PROBHD 5 mm CPPTCI 1H
 PULPROG zg30
 ID 65536
 SOLVENT MeOD
 NS 4
 DS 2
 SWH 9803.922 Hz
 FIDRES 0.149596 Hz
 AQ 3.3423359 sec
 RG 111.35
 DW 51.000 usec
 DE 59.79 usec
 TE 295.0 K
 D1 1.00000000 sec
 TD0 1


==== CHANNEL f1 =====
 SFO1 700.1342008 MHz
 NUC1 1H
 P1 8.00 usec
 PLW1 15.30000019 W

F2 - Processing parameters
 SI 65536
 SF 700.1300134 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



59

¹³C NMR (CD₃OD)




Current Data Parameters
 NAME 03232016-11-rjmg-mc410-A
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160323
 Time 21.48
 INSTRUM spect
 PROBHD 5 mm CPPBBO BB
 PULPROG udefr
 TD 21424
 SOLVENT MeOD
 NS 1600
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 19.22 usec
 TE 295.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 D12 0.0000200 sec
 D20 200.0000000 sec
 TDC 1


----- CHANNEL f1 -----
 SFO1 125.7716219 MHz
 NUC1 13C
 P1 11.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 63.0000000 W
 SPNAM[5] Crp60comp.4
 SPOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 11.64700031 W
 SPNAM[8] Crp60,0.5,20.1
 SPOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 11.64700031 W

----- CHANNEL f2 -----
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 14.0000000 W
 PLW12 0.3150000 W

F2 - Processing parameters
 SI 262144
 SF 125.7576120 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40



60
¹H NMR (CD₃OD)



1.00
 1.35
 2.14
 1.20
 7.79
 1.32

1.06
 1.00

1.14
 1.07
 0.78
 1.25

3.06




Current Data Parameters
 NAME 03142016-30-rjmg-mc410-A
 EXPNO 10
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20160314
 Time 21.02
 INSTRUM spect
 PROBHD 5 mm CPPBBO BB
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 64
 DS 2
 SWH 7002.801 Hz
 FIDRES 0.106854 Hz
 AQ 4.6792703 sec
 RG 64
 DW 71.400 usec
 DE 10.95 usec
 TE 295.0 K
 D1 1.00000000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 500.1330008 MHz
 NUC1 1H
 P1 12.50 usec
 PLW1 14.00000000 W

F2 - Processing parameters
 SI 65536
 SF 500.1300097 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



60
¹³C NMR (CD₃OD)




```
Current Data Parameters
NAME      03142016-30-rjmg-mc410-A
EXPNO     12
PROCNO    1

F2 - Acquisition Parameters
Date_     20160314
Time      22.53
INSTRUM   spect
PROBHD    5 mm CPPBBO BB
PULPROG   udefT
TD         21424
SOLVENT   MeOD
NS         1600
DS         0
SWH        29761.904 Hz
FIDRES     1.389185 Hz
AQ         0.3599232 sec
RG         128
DW         16.800 usec
DE         19.22 usec
TE         295.0 K
D1         3.00000000 sec
D11        0.03000000 sec
D12        0.00002000 sec
D20        200.00000000 sec
TD0        1

===== CHANNEL f1 =====
SFO1      125.7716219 MHz
NUC1       13C
P1         11.00 usec
P13        2000.00 usec
P26         500.00 usec
PLW1       63.00000000 W
SPNAM[5]   Crp60comp.4
SPOAL5     0.500
SPOFFS5    0 Hz
SPW5       11.64700031 W
SPNAM[8]   Crp60,0.5,20.1
SPOAL8     0.500
SPOFFS8    0 Hz
SPW8       11.64700031 W


----- CHANNEL f2 -----
SFO2      500.1320005 MHz
NUC2       1H
CPDPRG[2] waltz65
PCPD2     80.00 usec
PLW2      14.00000000 W
PLW12     0.31500000 W

F2 - Processing parameters
SI         262144
SF         125.7576119 MHz
WDW        EM
SSB        0
LB         2.00 Hz
GB         0
PC         1.40
```



60

$^{19}\text{F}\{^1\text{H}\}$ NMR (CD_3OD)




Current Data Parameters
 NAME 03152016-2-rjmg-mc410-M
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160315
 Time 16.50
 INSTRUM AVI400
 PROBHD 5 mm PABBO BB/
 PULPROG zgfhigqn.3.and
 TD 65536
 SOLVENT MeOD
 NS 64
 DS 4
 SWH 30000.000 Hz
 FIDRES 0.457764 Hz
 AQ 1.0922667 sec
 RG 128
 DW 16.667 usec
 DE 8.37 usec
 TE 295.3 K
 D1 1.0000000 sec
 D11 0.0300000 sec
 D12 0.0000200 sec
 TD0 1

===== CHANNEL f1 =====
 SFO1 376.4569514 MHz
 NUC1 ^{19}F
 P1 15.00 usec
 PLW1 17.0000000 W


===== CHANNEL f2 =====
 SFO2 400.1316005 MHz
 NUC2 ^1H
 CPDPRG[2] waltz65
 PCPD2 90.00 usec
 PLW2 16.0000000 W
 PLW12 0.48688999 W

F2 - Processing parameters
 SI 65536
 SF 376.4983662 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



60
¹⁹F NMR (CD₃OD)

-115.16
 -115.18
 -115.18
 -115.20
 -115.20
 -115.22



-114.9 -115.0 -115.1 -115.2 -115.3 -115.4 ppm




Current Data Parameters
 NAME 03142016-30-rjmg-mc410-A
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160314
 Time 21.06
 INSTRUM spect
 PROBHD 5 mm CFPBBO BB
 PULPROG zg
 TD 65536
 SOLVENT MeOD
 NS 32
 DS 4
 SWH 37500.000 Hz
 FIDRES 0.572205 Hz
 AQ 0.8738133 sec
 RG 20.2
 DW 13.333 usec
 DE 18.16 usec
 TE 295.0 K
 D1 1.0000000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 470.5406119 MHz
 NUC1 19F
 P1 15.00 usec
 PLW1 15.0000000 W

F2 - Processing parameters
 SI 65536
 SF 470.5923772 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



Current Data Parameters
NAME 03212016-17-rjmg-mc410-F
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160321
Time 16.28
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65536
SOLVENT MeOD
NS 8
DS 2
SWH 6996.269 Hz
FIDRES 0.106755 Hz
AQ 4.6836395 sec
RG 121.22
DW 71.467 usec
DE 11.38 usec
TE 295.0 K
D1 1.00000000 sec
TD0 1

----- CHANNEL f1 -----
SFO1 499.9329996 MHz
NUC1 1H
P1 10.60 usec
PLW1 16.00000000 W

F2 - Processing parameters
SI 65536
SF 499.9300094 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




Current Data Parameters
NAME 03222016-1-rjmg-mc410-A
EXPNO 10
PROCNO 1



F2 - Acquisition Parameters
Date_ 20160322
Time_ 21.11
INSTRUM spect
PROBHD 5 mm CPPBB0 BB
PULPROG udef1
TD 21424
SOLVENT MeOD
NS 2000
DS 0
SWH 29761.904 Hz
FIDRES 1.389185 Hz
AQ 0.3599232 sec
RG 128
DW 16.800 usec
DE 19.22 usec
TE 295.0 K
D1 3.00000000 sec
D11 0.03000000 sec
D12 0.00002000 sec
D20 200.00000000 sec
TD0 1

===== CHANNEL f1 =====
SFO1 125.7716219 MHz
NUC1 13C
P1 11.00 usec
P13 2000.00 usec
P26 500.00 usec
PLW1 63.00000000 W
SPNAM[5] Crp60comp.4
SPCAL5 0.500
SPOFFS5 0 Hz
SPW5 11.64700031 W
SPNAM[8] Crp60,0.5,20.1
SPCAL8 0.500
SPOFFS8 0 Hz
SPW8 11.64700031 W

===== CHANNEL f2 =====
SFO2 500.1320005 MHz
NUC2 1H
CPDPRG[2] waltz65
PCPD2 80.00 usec
PLW2 14.00000000 W
PLW12 0.31500000 W

F2 - Processing parameters
SI 262144
SF 125.7576123 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 1.40





61
¹³C NMR (CD₃OD)




Current Data Parameters
 NAME 03222016-1-rjmg-mc410-A
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160322
 Time 21.11
 INSTRUM spect
 PROBHD 5 mm CFPBBO BB
 PULPROG udef1
 TD 21424
 SOLVENT MeOD
 NS 2000
 DS 0
 SWH 29761.904 Hz
 FIDRES 1.389185 Hz
 AQ 0.3599232 sec
 RG 128
 DW 16.800 usec
 DE 19.22 usec
 TE 295.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 D12 0.0000200 sec
 D20 200.0000000 sec
 TD0 1

===== CHANNEL f1 =====
 SFO1 125.7716219 MHz
 NUC1 13C
 P1 11.00 usec
 P13 2000.00 usec
 P26 500.00 usec
 PLW1 63.0000000 W
 SPNAM[5] Crp60comp.4
 SPOAL5 0.500
 SPOFFS5 0 Hz
 SPW5 11.64700031 W
 SPNAM[8] Crp60,0.5,20.1
 SPOAL8 0.500
 SPOFFS8 0 Hz
 SPW8 11.64700031 W

===== CHANNEL f2 =====
 SFO2 500.1320005 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 14.0000000 W
 PLW12 0.3150000 W

F2 - Processing parameters
 SI 262144
 SF 125.7576123 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40



61

$^{19}\text{F}\{^1\text{H}\}$ NMR (CD_3OD)

-115.20

-80 -90 -100 -110 -120 -130 -140 ppm



Current Data Parameters
 NAME 03212016-17-rjmg-mc410-F
 EXPNO 11
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20160321
 Time 16.31
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgfhigq.3.and
 TD 65536
 SOLVENT MeOD
 NS 32
 DS 4
 SWH 37500.000 Hz
 FIDRES 0.572205 Hz
 AQ 0.8738133 sec
 RG 77.86
 DW 13.333 usec
 DE 6.75 usec
 TE 295.0 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 D12 0.00002000 sec
 TD0 1

----- CHANNEL f1 -----
 SFO1 470.3524446 MHz
 NUC1 19F
 P1 14.60 usec
 PLW1 48.00000000 W

----- CHANNEL f2 -----
 SFO2 499.9319997 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 80.00 usec
 PLW2 16.00000000 W
 PLW12 0.27563000 W

F2 - Processing parameters
 SI 65536
 SF 470.4041892 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




Current Data Parameters
NAME 03232016-5-rjmg-mc410-F
EXPNO 10
PROCNO 1


F2 - Acquisition Parameters
Date_ 20160323
Time 14.45
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 65536
SOLVENT MeOD
NS 32
DS 4
SWH 37500.000 Hz
FIDRES 0.572205 Hz
AQ 0.8738133 sec
RG 121.22
DW 13.333 usec
DE 6.75 usec
TE 295.0 K
D1 1.0000000 sec
TD0 1

===== CHANNEL f1 =====
SFO1 470.3524446 MHz
NUC1 19F
P1 14.60 usec
PLW1 48.0000000 W


F2 - Processing parameters
SI 65536
SF 470.4041892 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00






07012016-7-rjmg-mc410-H.10.fid
19F Observe without 1H decoupling - SW 80 ppm
MJC Br Cys HPLC 1



^{19}F NMR (D_2O) of **64** and **65**










67


¹H NMR (CD₃Cl)






^{13}C NMR (CD_3Cl)






68


¹H NMR (CDCl₃)






68


^{13}C NMR (CDCl_3)






69


¹H NMR (CD₃OD)






70

¹H NMR (CD₃OD)





70

^{13}C NMR (CD_3OD)

171.92
171.76
171.62

155.59

135.98
134.91
129.32
128.80
128.67
127.20
124.55
124.07
120.78
118.21
111.75
104.86

80.24

55.02
53.58
52.45
48.98


37.87


28.49
28.35

18.40


30 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0


f1 (ppm)







71
¹³C NMR (CD₃OD)






72
¹H NMR (d₆-DMSO)








72

^{13}C NMR (d_6 -DMSO)



Enantiopurity analyses by UPLC using Marfey's Reagent





	Name	Retention Time	Area	% Area	Height	Int Type	Amount	Units	Peak Type	Peak Codes	Match_Criteria	Purity
1		2.210	2588715	74.91	1409209	bb			Unknown			
2		2.430	867178	25.09	486339	bb			Unknown			

